HAEMOPHILUS ADHERENCE AND PENETRATION PROTEINS

Abstract: Haemophilus adhesion and penetration proteins, nucleic acids, vaccines and monoclonal antibodies are provided.

Description: HAEMOPHILUS ADHERENCE AND PENETRATION PROTEINS FIELD OF THE INVENTION The invention relates to Haemophil us adhesion and penetration proteins, nucleic acids, and vaccines. BACKGROUND OF THE INVENTION Most bacterial diseases begin with colonization of a particular mucosal surface (Beachey et al. , 1981, J. Infect. Dis. 143:325-345) . Successful colonization requires that an organism overcome mechanical cleansing of the mucosal surface and evade the local immune response. The process of colonization is dependent upon specialized microbial factors that promote binding to host cells (Hultgren et al. , 1993 Cell, 73:887-901) . In some cases the colonizing organism will subsequently enter (invade) these cells and survive intracellularly (Falkow, 1991, Cell 65:1099-1102) . Haemophilus influenzae is a common commensal organism of the human respiratory tract (Kuklinska and Kilian, 1984, Eur. J. Clin. Microbiol . 3:249-252) . It is a human-specific organism that normally resides in the human nasopharynx and must colonize this site in order to avoid extinction. This microbe has a number of surface structures capable of promoting attachment to host cells (Guerina et al . , 1982, J. Infect. Dis. 146:564; Pichichero et al . , 1982, Lancet ii:960-962; St. Geme et al . , 1993, Proc. Natl. Acad. Sci. U.S.A. 90:2875-2879) . In addition, H. influenzae has acquired the capacity to enter and survive within these cells (Forsgren et al . , 1994, Infect. Immun. 62:673-679; St. Geme and Falkow, 1990, Infect. Immun. 58:4036-4044; St. Geme and Falkow, 1991, Infect. Immun. 59:1325-1333, Infect. Immun. 59:3366-3371) . As a result, this bacterium is an important cause of both localized respiratory tract and systemic disease (Turk, 1984, J. Med. Microbiol . 18:1-16) . Nonencapsulated, non-typable strains account for the majority of local disease (Turk, 1984, supra) ; in contrast, serotype b strains, which express a capsule composed of a polymer of ribose and ribitol-5-phosphate (PRP) , are responsible for over 95% of cases of H. influenzae systemic disease (Turk, 1982, Clinical importance of Haemophilus influenzae, p. 3-9. In S.H. Sell and P.F. Wright (ed.), Haemophilus influenzae epidemiology, immunology, and prevention of disease. Elsevier/North-Holland Publishing Co., New York) . The initial step in the pathogenesis of disease due to H. influenzae involves colonization of the upper respiratory mucosa (Murphy et al . , 1987, J. Infect. Dis. 5:723-731) . Colonization with a particular strain may persist for weeks to months, and most individuals remain asymptomatic throughout this period (Spinola et al . , 1986, I. Infect. Dis. 154:100-109) . However, in certain circumstances colonization will be followed by contiguous spread within the respiratory tract, resulting in local disease in the middle ear, the sinuses, the conjunctiva, or the lungs. Alternatively, on occasion bacteria will penetrate the nasopharyngeal epithelial barrier and enter the bloodstream. In vi tro observations and animal studies suggest that bacterial surface appendages called pili (or fimbriae) play an important role in H. influenzae colonization. In 1982 two groups reported a correlation between piliation and increased attachment to human oropharyngeal epithelial cells and erythrocytes (Guerina et al . , supra; Pichichero et al . , supra) . Other investigators have demonstrated that anti-pilus antibodies block in vi tro attachment by piliated H. infl uenzae (Forney et al . , 1992, J. Infect. Dis. 165:464-470; van Alphen et al . , 1988, Inf ct. Immun. 56:1800-1806) . Recently Weber et al . insertionally inactivated the pilus structural gene in an H. infl uenzae type b strain and thereby eliminated expression of pili; the resulting mutant exhibited a reduced capacity for colonization of year-old monkeys (Weber et al . , 1991, Infect. Immun. 59:4724-4728) . A number of reports suggest that nonpilus factors also facilitate Haemophilus colonization. Using the human nasopharyngeal organ culture model, Farley et al . (1986, J. Infect. Dis. 161:274-280) and Loeb et al . (1988, Infect. Immun. 49:484-489) noted that nonpiliated type b strains were capable of mucosal attachment. Read and coworkers made similar observations upon examining nontypable strains in a model that employs nasal turbinate tissue in organ culture (1991, J. Infect. Dis. 163 :549-558) . In the monkey colonization study by Weber et al . (1991, supra) , nonpiliated organisms retained a capacity for colonization, though at reduced densities; moreover, among monkeys originally infected with the piliated strain, virtually all organisms recovered from the nasopharynx were nonpiliated. All of these observations are consistent with the finding that nasopharyngeal isolates from children colonized with H. influenzae are frequently nonpiliated (Mason et al . , 1985, Infect. Immun. 49:98-103; Brinton et al . , 1989, Pediatr. Infect. Dis. J. 8:554-561) . Previous studies have shown that H. infl uenzae are capable of entering (invading) cultured human epithelial cells via a pili-independent mechanism (St. Geme and Falkow, 1990, supra; St. Geme and Falkow, 1991, supra) . Although H. influenzae is not generally considered an intracellular parasite, a recent report suggests that these in vi tro findings may have an in vivo correlate (Forsgren et al., 1994, supra) . Forsgren and coworkers examined adenoids from 10 children who had their adenoids removed because of longstanding secretory otitis media or adenoidal hypertrophy. In all 10 cases there were viable intracellular H. influenzae. Electron microscopy demonstrated that these organisms were concentrated in the reticular crypt epithelium and in macrophage-like cells in the subepithelial layer of tissue. One possibility is that bacterial entry into host cells provides a mechanism for evasion of the local immune response, thereby allowing persistence in the respiratory tract. Thus, a vaccine for the therapeutic and prophylactic treatment of Haemophilus infection is desirable. Accordingly, it is an object of the present invention to provide for recombinant Haemophilus Adherence and Penetration (HAP) proteins and variants thereof, and to produce useful quantities of these HAP proteins using recombinant DNA techniques. It is a further object of the invention to provide recombinant nucleic acids encoding HAP proteins, and expression vectors and host cells containing the nucleic acid encoding the HAP protein. An additional object of the invention is to provide monoclonal antibodies for the diagnosis of Haemophilus infection. A further object of the invention is to provide methods for producing the HAP proteins, and a vaccine comprising the HAP proteins of the present invention. Methods for the therapeutic and prophylactic treatment of Haemophilus infection are also provided. SUMMARY OF THE INVENTION In accordance with the foregoing objects, the present invention provides recombinant HAP proteins, and isolated or recombinant nucleic acids which encode the HAP proteins of the present invention. Also provided are expression vectors which comprise DNA encoding a HAP protein operably linked to transcriptional and translational regulatory DNA, and host cells which contain the expression vectors. The invention provides also provides methods for producing HAP proteins which comprises culturing a host cell transformed with an expression vector and causing expression of the nucleic acid encoding the HAP protein to produce a recombinant HAP protein. The invention also includes vaccines for Haemophilus influenzae infection comprising an HAP protein for prophylactic or therapeutic use in generating an immune response in a patient. Methods of treating or preventing Haemophilus influenzae infection comprise administering a vaccine. BRIEF DESCRIPTION OF THE DRAWINGS Figures 1A and IB depict light micrographs of H. influenzae strains DB117 (pGJB103) and DB117(pN187) incubated with Chang epithelial cells. Bacteria were incubated with an epithelial monolayer for 30 minutes before rinsing and straining with Gie sa stain. Figure 1A: H. influenzae strain DB117 carrying cloning vector alone (pGJB103) ; Figure IB: H. infl uenzae strain DB117 harboring recombinant plasmid pH187. Bar represents 3.5 μm. Figures 2A, 2B, 2C and 2D depict thin section transmission electron micrographs demonstrating interaction between H. influenzae strains N187 and DB117 (pN187) with Chang epithelial cells. Bacteria were incubated with epithelial monolayers for four hours before rinsing and processing for examination by transmission electron microscopy. Figure 2A: strain N187 associated with the epithelial cell surface and present in an intracellular location; Figure 2B: H. influenzae DB117 (pH187) in intimate contact with the epithelial cell surface; Figure 2C: strain DB117(pN187) in the process of entering an epithelial cell; Figure 2D: strain DB117(pN187) present in an intracellular location. Bar represents 1 μm. Figure 3 depicts outer membrane protein profiles of various strains. Outer membrane proteins were isolated on the basis of sarcosyl insolubility and resolved on a 10% SDS-polyacrylamide gel. Proteins were visualized by staining with Coomassie blue. Lane 1, H. influenzae strain DB117 (pGJB103) ; lane 2, strain DB117 (pN187) ; lane 3, strain DB117 (pJS106) ; lane 4, E. coli HB101 (pGJB103) ; lane 5, HB101 (pN187) . Note novel proteins at -160 kD and 45 kD marked by asterisks in lanes 2 and 3. Figure 4 depicts a restriction map of pN187 and derivatives and locations of mini-TnlO kan insertions. pN187 is a derivative of pGJB103 that contains an 8.5-kb Sau3AI fragment of chromosomal DNA from H. influenzae strain N187. Vector sequences are represented by hatched boxes. Letters above top horizontal line indicate restriction enzyme sites: Bg, Bgl l l ; C, Clal; E, EcoRI ; P, Pstl. Numbers and lollipops above top horizontal line show positions of mini-TnlO kan insertions; open lollipops represent insertions that have no effect on adherence and invasion, while closed lollipops indicate insertions that eliminate the capacity of pN187 to promote association with epithelial monolayers. Heavy horizontal line with arrow represents location of iap locus within pN187 and direction of transcription. (+) : recombinant plasmids that promote adherence and invasion; {-) : recombinant plasmids that fail to promote adherence and invasion. Figure 5 depicts the identification of plasmid-encoded proteins using the bacteriophage T7 expression system. Bacteria were radiolabeled with [ 35 S] methionine, and whole cell lysates were resolved on a 10% SDS- polyacrylamide gel. Proteins were visualized by autoradiography. Lane 1, E. coli XL-1 Blue(pT7-7) uninduced; lane 2, XL-1 Blue(pT7-7) induced with IPTG; lane 3, XL-1 Blue(pJS103) uninduced; lane 4, XL-1 Blue(pJS103) induced with IPTG; lane 5, XL-1 Blue(pJS104) uninduced; lane 6, XL-1 Blue(pJS104) induced with IPTG. The plasmids pJS103 and pJS104 are derivatives of pT7-7 that contain the 6.5-kb PstI fragment from pN187 in opposite orientations. Asterisk indicates overexpressed protein in XL-1 Blue (pJS104) . Figures 6A, 6B, and 6C depict the nucleotide sequence and predicted amino acid sequence of hap gene. Putative -10 and -35 sequences 5' to the hap coding sequence are underlined; a putative rho-independent terminator 3' to the hap stop codon is indicated with inverted arrows. The first 25 amino acids of the protein, which are boxed, represent the signal sequence. Figures 7A, 7B, 7C, 7D, 7E, 7F, 7G, and 7H depict a sequence comparison of the hap product and the cloned H. influenzae IgAl proteases. Amino acid homologies between the deduced hap gene product and the iga gene products from H. influenzae HK368, HK61, HK393, and HK793 are shown. Dashes indicate gaps introduced in the sequences in order to obtain maximal homology. A consensus sequence for the five proteins is shown on the lower line. The conserved serine-type protease catalytic domain is underlined, and the common active site serine is denoted by an asterisk. The conserved cysteines are also indicated by asterisks. Figure 8 depicts the IgAl protease activity assay. Culture supernatants were assayed for the ability to cleave IgAl. Reaction mixtures were resolved on a 10% SDS-polyacrylamide gel and then transferred to a nitrocellulose membrane. The membrane was probed with antibody against human IgAl heavy chain. Lane 1, H. influenzae strain N187; lane 2, strain DB117 (pGJB103) ; lane 3, strain DB117 (pN187) . The cleavage product patterns suggest that strain N187 contains a type 2 IgAl protease while strains DB117 (pGJB103) and DB117(pN187) contain a type 1 enzyme. The upper band of -70-kD seen with the DB117 derivatives represents intact IgAl heavy chain. Figures 9A and 9B depict southern analysis of chromosomal DNA from strain H. influenzae N187, probing with hap versus iga . DNA fragments were separated on a 0.7% agarose gel and transferred bidirectionally to nitrocellulose membranes prior to probing with either hap or iga . Lane 1, N187 chromosomal DNA digested with EcoRI ; lane 2, N187 chromosomal DNA digested with Bgl l l ; lane 3, N187 chromosomal DNA digested with BaπMI; lane 4, the 4.8-kb Clal-PstI fragment from pN187 that contains the intact hap gene. Figure 9A: Hybridization with the 4.8-kb Clal-PstI fragment containing the hap gene; Figure 9B: hybridization with the iga gene from H. influenzae strain Rd, carried as a 4.8-kb Clal-EcoRI fragment in pVD116. Figure 10 depicts a SDS-polyacrylamide gel of secreted proteins. Bacteria were grown to late log phase, and culture supernatants were precipitated with trichloroacetic acid and then resolved on a 10% SDS- polyacrylamide gel. Proteins were visualized by staining with Coomassie blue. Lane 1, H. influenzae strain DB117 (pGJB103) ; lane 2, DB117 (pN187) ; lane 3, DB117(pJS106) ; lane 4, DB117 (pJS102) ; lane 5, DB117(pJS105) ; lane 6, DB117 (TnlO-18) ; lane 7, DB117(TnlO-4' ) ; lane 8, DB117 (TnlO-30) ; lane 9, DB117(TnlO-16) ; lane 10, DB117 (TnlO-10) ; lane II, DB117(Tnl0-8) ; lane 12, N187. Asterisk indicates 110-kD secreted protein encoded by hap. DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel Haemophilus Adhesion and Penetration (HAP) proteins. In a preferred embodiment, the HAP proteins are from Haemophilus strains, and in the preferred embodiment, from Haemophilus influenza . However, using the techniques outlined below, HAP proteins from other Haemophilus infl uenzae strains, or from other bacterial species such as Neiεseria spp. or Bordetalla spp. may also be obtained. A HAP protein may be identified in several ways. A HAP nucleic acid or HAP protein is initially identified by substantial nucleic acid and/or amino acid sequence homology to the sequences shown in Figure 6. Such homology can be based upon the overall nucleic acid or amino acid sequence. The HAP proteins of the present invention have limited homology to Haemophilus influenzae and N. gonorrhoeae serine-type IgAl proteases. This homology, shown in Figure 7, is approximately 30-35% at the amino acid level, with several stretches showing 55-60% identity, including amino acids 457-549, 399-466, 572-622, and 233-261. However, the homology between the HAP protein and the IgAl protease is considerably lower than the similarity among the IgAl proteases themselves. In addition, the full length HAP protein has homology to Tsh, a hemagglutinin expressed by an avian E. coli strain (Provence and Curtiss 1994, Infect. Immun. 62:1369-1380) . The homology is greatest in the N- terminal half of the proteins, and the overall homology is 30.5% homologous. The full length HAP protein also has homology with pertactin, a 69 kD outer membrane protein expressed by B . pertussis, with the middle portion of the proteins showing 39% homology. Finally, HAP has 34 - 52% homology with six regions of HpmA, a calcium-independent hemolysin expressed by Proteus mirabilis (Uphoff and Welch, 1990, J. Bacteriol . 172:1206-1216) . As used herein, a protein is a "HAP protein" if the overall homology of the protein sequence to the amino acid sequence shown in Figure 6 is preferably greater than about 40 - 50%, more preferably greater than about 60% and most preferably greater than 80%. In some embodiments the homology will be as high as about 90 to 95 or 98%. This homology will be determined using standard techniques known in the art, such as the Best Fit sequence program described by Devereux et al . , Nucl . Acid Res . 12:387-395 (1984) . The alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer amino acids than the protein shown in Figure 6, it is understood that the percentage of homology will be determined based on the number of homologous amino acids in relation to the total number of amino acids. Thus, for example, homology of sequences shorter than that shown in Figure 6, as discussed below, will be determined using the number of amino acids in the shorter sequence. HAP proteins of the present invention may be shorter than the amino acid sequence shown in Figure 6. As shown in the Examples, the HAP protein may undergo post- translational processing similar to that seen for the serine-type IgAl proteases expressed by Haemophilus influenzae and N. gonorrhoeae . These proteases are synthesized as preproteins with three functional domains: the N-terminal signal peptide, the protease, and a C-terminal helper domain. Following movement of these proteins into the periplasmic space, the carboxy terminal β-domain of the proenzyme is inserted into the outer membrane, possibly forming a pore (Poulsen et al . , 1989, Infect. Immun. 57:3097-3105; Pohlner et al . , 1987, Nature (London) . 325:458-462; Klauser et al . , 1992, EMBO J. 11:2327-2335; Klauser et al . , 1993, J. Mol . Biol . 234:579-593) . Subsequently the amino end of the protein is exported through the outer membrane, and autoproteolytic cleavage occurs to result in secretion of the mature 100 to 106-kD protease. The 45 to 56-kD C-terminal β-domain remains associated with the outer membrane following the cleavage event. As shown in the Examples, the HAP nucleic acid is associated with expression of a 160 kD outer membrane protein. The secreted gene product is an approximately 110 kD protein, with the simultaneous appearance of a 45 kD outer membrane protein. The 45 kD protein appears to correspond to amino acids from about 960 to about 1394 of Figure 6. Any one of these proteins is considered a HAP protein for the purposes of this invention. Thus, in a preferred embodiment, included within the defintion of HAP proteins are portions or fragments of the sequence shown in Figure 6. The fragments may be fragments of the entire sequence, the 110 kD sequence, or the 45 kD sequence. Generally, the HAP protein fragments may range in size from about 10 amino acids to about 1900 amino acids, with from about 50 to about 1000 amino acids being preferred, and from about 100 to about 500 amino acids also preferred. Particularly preferred fragments are sequences unique to HAP; these sequences have particular use in cloning HAP proteins from other organisms or to generate antibodies specific to HAP proteins. Unique sequences are easily identified by those skilled in the art after examination of the HAP protein sequence and comparison to other proteins; for example, by examination of the sequence alignment shown in Figure 7. For instance, as compared to the IgA proteases, unique sequences include, but are not limited to, amino acids 11-14, 16-22, 108-120, 155-164, 257-265, 281-288, 318-336, 345-353, 398-416, 684-693, 712-718, 753-761, 871-913, 935-953, 985-1008, 1023-1034, 1067- 1076, 1440-1048, 1585-1592, 1631-1639, 1637-1648, 1735- 1743, 1863-1871, 1882-1891, 1929-1941, and 1958-1966 (using the numbering of Figure 7) . HAP protein fragments which are included within the definition of a HAP protein include N- or C-terminal truncations and deletions which still allow the protein to be biologically active; for example, which still exhibit proteolytic activity in the case of the 110 kD putative protease sequence. In addition, when the HAP protein is to be used to generate antibodies, for example as a vaccine, the HAP protein must share at least one epitope or determinant with either the full length protein, the 110 kD protein or the 45 kD protein, shown in Figure 6. In a preferred embodiment, the epitope is unique to the HAP protein; that is, antibodies generated to a unique epitope exhibit little or no cross-reactivity with other proteins. By "epitope" or "determinant" herein is meant a portion of a protein which will generate and/or bind an antibody. Thus, in most instances, antibodies made to a smaller HAP protein will be able to bind to the full length protein. In some embodiments, the fragment of the HAP protein used to generate antibodies are small; thus, they may be used as haptens and coupled to protein carriers to generate antibodies, as is known in the art. Preferably, the antibodies are generated to a portion of the HAP protein which remains attached to the Haemophilus influenzae organism. For example, the HAP protein can be used to vaccinate a patient to produce antibodies which upon exposure to the Haemophilus infl uenzae organism (e.g. during a subsequent infection) bind to the organism and allow an immune response. Thus, in one embodiment, the antibodies are generated to the roughly 45 kD fragment of the full length HAP protein. Preferably, the antibodies are generated to the portion of the 45 kD fragment which is exposed at the outer membrane. In an alternative embodiment, the antibodies bind to the mature secreted 110 kD fragment. For example, as explained in detail below, the HAP proteins of the present invention may be administered therapeutically to generate neutralizing antibodies to the 110 kD putative protease, to decrease the undesirable effects of the 100 kD fragment. In the case of the nucleic acid, the overall homology of the nucleic acid sequence is commensurate with amino acid homology but takes into account the degeneracy in the genetic code and codon bias of different organisms. Accordingly, the nucleic acid sequence homology may be either lower or higher than that of the protein sequence. Thus the homology of the nucleic acid sequence as compared to the nucleic acid sequence of Figure 6 is preferably greater than 40%, more preferably greater than about 60% and most preferably greater than 80%. In some embodiments the homology will be as high as about 90 to 95 or 98%. In one embodiment, the nucleic acid homology is determined through hybridization studies. Thus, for example, nucleic acids which hybridize under high stringency to all or part of the nucleic acid sequence shown in Figure 6 are considered HAP protein genes. High stringency conditions include washes with 0.1XSSC at 65°C for 2 hours. The HAP proteins and nucleic acids of the present invention are preferably recombinant. As used herein, "nucleic acid" may refer to either DNA or RNA, or molecules which contain both deoxy- and ribonucleotides. The nucleic acids include genomic DNA, cDNA and oligonucleotides including sense and anti-sense nucleic acids. Specifically included within the definition of nucleic acid are anti-sense nucleic acids. An anti- sense nucleic acid will hybridize to the corresponding non-coding strand of the nucleic acid sequence shown in Figure 6, but may contain ribonucleotides as well as deoxyribonucleotides . Generally, anti-sense nucleic acids function to prevent expression of mRNA, such that a HAP protein is not made, or made at reduced levels. The nucleic acid may be double stranded, single stranded, or contain portions of both double stranded or single stranded sequence. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro by the manipulation of nucleic acid by endonucleases, in a form not normally found in nature. Thus an isolated HAP protein gene, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e. using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-reco binantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated away from some or all of the proteins and compounds with which it is normally associated in its wild type host, or found in the absence of the host cells themselves. Thus, the protein may be partially or substantially purified. The definition includes the production of a HAP protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of a inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions. Also included with the definition of HAP protein are HAP proteins from other organisms, which are cloned and expressed as outlined below. In the case of anti-sense nucleic acids, an anti-sense nucleic acid is defined as one which will hybridize to all or part of the corresponding non-coding sequence of the sequence shown in Figure 6. Generally, the hybridization conditions used for the determination of anti-sense hybridization will be high stringency conditions, such as 0.1XSSC at 65°C. Once the HAP protein nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire HAP protein nucleic acid. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant HAP protein nucleic acid can be further used as a probe to identify and isolate other HAP protein nucleic acids. It can also be used as a "precursor" nucleic acid to make modified or variant HAP protein nucleic acids and proteins. Using the nucleic acids of the present invention which encode HAP protein, a variety of expression vectors are made. The expression vectors may be either self- replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the HAP protein. "Operably linked" in this context means that the transcriptional and translational regulatory DNA is positioned relative to the coding sequence of the HAP protein in such a manner that transcription is initiated. Generally, this will mean that the promoter and transcriptional initiation or start sequences are positioned 5' to the HAP protein coding region. The transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the HAP protein; for example, transcriptional and translational regulatory nucleic acid sequences from Bacillus will be used to express the HAP protein in Bacillus. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells. In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences. Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention. In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art . In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used. The HAP proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a HAP protein, under the appropriate conditions to induce or cause expression of the HAP protein. The conditions appropriate for HAP protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield. Appropriate host cells include yeast, bacteria, archebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Drosophila melanαaster cells, Saccharomvces cerevisiae and other yeasts, E. coli. Bacillus subtilis. SF9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, and HeLa cells, immortalized mammalian myeloid and lymphoid cell lines. In a preferred embodiment, HAP proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. A suitable bacterial promoter is any nucleic acid sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of the coding sequence of HAP protein into mRNA. A bacterial promoter has a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose and maltose, and sequences derived from biosynthetic enzymes such as tryptophan. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. In E. coli , the ribosome binding site is called the Shine- Delgarno (SD) sequence and includes an initiation codon and a sequence 3-9 nucleotides in length located 3 - 11 nucleotides upstream of the initiation codon. The expression vector may also include a signal peptide sequence that provides for secretion of the HAP protein in bacteria. The signal sequence typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell, as is well known in the art. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria) . The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kana ycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known. in the art, and include vectors for Bacillus subtilis, E. coli , Streptococcus cremoris, and Streptococcus lividanε, among others. The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others. In one embodiment, HAP proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art. Briefly, baculovirus is a very large DNA virus which produces its coat protein at very high levels. Due to the size of the baculoviral genome, exogenous genes must be placed in the viral genome by recombination. Accordingly, the components of the expression system include: a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the HAP protein; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene into the baculovirus genome) ; and appropriate insect host cells and growth media. Mammalian expression systems are also known in the art and are used in one embodiment. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence for HAP protein into mRNA. A promoter will have a transcription initiating region, which is usually place proximal to the 5' end of the coding sequence, and a TATA box, using a located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, typically located within 100 to 200 base pairs upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, and herpes simplex virus promoter. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-translational cleavage and polyadenylation. Examples of transcription terminator and polyadenlytion signals include those derived form SV40. The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide (s) inliposomes, and direct microinjection of the DNA into nuclei. In a preferred embodiment, HAP protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polvmorpha. Kluyveromvces fraσilis and K. lactis, Pichia cruillerimondii and P. pastoris. Schizosaccharomyces pombe, and Yarrowia lipolvtica. Preferred promoter sequences for expression in yeast include the inducible GAL1,10 promoter, the promoters from alcohol dehydrogenase, enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3- phosphate-dehydrogenase , hexokinase , phosphofructokinase, 3-phosphoglycerate mutase, pyruvate kinase, and the acid phosphatase gene. Yeast selectable markers include ADE2, HIS4, LEU2, TRPl, andALG7, which confers resistance to tunicamycin; the G418 resistance gene, which confers resistance to G418; and the CUP1 gene, which allows yeast to grow in the presence of copper ions . A recombinant HAP protein may be expressed intracellularly or secreted. The HAP protein may also be made as a fusion protein, using techniques well known in the art. Thus, for example, if the desired epitope is small, the HAP protein may be fused to a carrier protein to form an immunogen. Alternatively, the HAP protein may be made as a fusion protein to increase expression. Also included within the definition of HAP proteins of the present invention are amino acid sequence variants. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the HAP protein, using cassette mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant HAP protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the HAP protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below. While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed HAP protein variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, M13 primer mutagenesis. Screening of the mutants is done using assays of HAP protein activities; for example, mutated HAP genes are placed in HAP deletion strains and tested for HAP activity, as disclosed herein. The creation of deletion strains, given a gene sequence, is known in the art. For example, nucleic acid encoding the variants may be expressed in a Haemophilus influenzae strain deficient in the HAP protein, and the adhesion and infectivity of the variant Haemophilus influenzae evaluated. Alternatively, the variant HAP protein may be expressed and its biological characteristics evaluated, for example its proteolytic activity. Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to 30 residues, although in some cases deletions may be much larger, as for example when one of the domains of the HAP protein is deleted. Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the HAP protein are desired, substitutions are generally made in accordance with the following chart: Chart I Original Residue Exemplary Substitutions Ala Ser Arg Lys Asn Gin, His Asp Glu Cys Ser Gin Asn Glu Asp Gly Pro His Asn, Gin He Leu, Val Leu He, Val Lys Arg, Gin, Glu Met Leu, He Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe Val He, Leu Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those shown in Chart I. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide' s properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl , valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine. The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analogue, although variants also are selected to modify the characteristics of the polypeptide as needed. Alternatively, the variant may be designed such that the biological activity of the HAP protein is altered. For example, the proteolytic activity of the larger 110 kD domain of the HAP protein may be altered, through the substitution of the amino acids of the active site. The putative catalytic domain of this protein is GDSGSPMF, with the first serine corresponding to the active site serine characteristic of serine type proteases. The residues of the active site may be individually or simultaneously altered to decrease or eliminate proteolytic activity. This may be done to decrease the toxicity or side effects of the vaccine. Similarly, the cleavage site between the 45 kD domain and the 100 kD domain may be altered, for example to eliminate proteolytic processing to form the two domains. Putatively this site is at residue 960. In a preferred embodiment, the HAP protein is purified or isolated after expression. HAP proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the HAP protein may be purified using a standard anti- HAP antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful . For general guidance in suitable purification techniques, see Scopes, R., Protein Purification, Springer-Verlag, NY (1982) . The degree of purification necessary will vary depending on the use of the HAP protein. In some instances no purification will be necessary. Once expressed and purified if necessary, the HAP proteins are useful in a number of applications. For example, the HAP proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify antibodies from samples obtained from animals or patients exposed to the Haemophilus influenzae organism. The purified antibodies may then be used as outlined below. Additionally, the HAP proteins are useful to make antibodies to HAP proteins. These antibodies find use in a number of applications. In a preferred embodiment, the antibodies are used to diagnose the presence of an Haemophilus influenzae infection in a sample or patient. This will be done using techniques well known in the art; for example, samples such as blood or tissue samples may be obtained from a patient and tested for reactivity with the antibodies, for example using standard techniques such as ELISA. In a preferred embodiment, monoclonal antibodies are generated to the HAP protein, using techniques well known in the art. As outlined above, the antibodies may be generated to the full length HAP protein, or a portion of the HAP protein. Antibodies generated to HAP proteins may also be used in passive immunization treatments, as is known in the art . Antibodies generated to unique sequences of HAP proteins may also be used to screen expression libraries from other organisms to find, and subsequently clone, HAP nucleic acids from other organisms. In one embodiment, the antibodies may be directly or indirectly labelled. By "labelled" herein is meant a compound that has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the compound at any position. Thus, for example, the HAP protein antibody may be labelled for detection, or a secondary antibody to the HAP protein antibody may be created and labelled. In one embodiment, the antibodies generated to the HAP proteins of the present invention are used to purify or separate HAP proteins or the Haemophilus influenzae organism from a sample. Thus for example, antibodies generated to HAP proteins which will bind to the Haemophilus infl uenzae organism may be coupled, using standard technology, to affinity chromatography columns. These columns can be used to pull out the Haemophilus organism from environmental or tissue samples. Alternatively, antibodies generated to the soluble 110 kD portion of the full-length portion of the protein shown in Figure 7 may be used to purify the 110 kD protein from samples. In a preferred embodiment, the HAP proteins of the present invention are used as vaccines for the prophylactic or therapeutic treatment of a Haemophilus influenzae infection in a patient. By "vaccine" herein is meant an antigen or compound which elicits an immune response in an animal or patient. The vaccine may be administered prophylactically, for example to a patient never previously exposed to the antigen, such that subsequent infection by the Haemophilus influenzae organism is prevented. Alternatively, the vaccine may be administered therapeutically to a patient previously exposed or infected by the Haemophilus influenzae organism. While infection cannot be prevented, in this case an immune response is generated which allows the patient's immune system to more effectively combat the infection. Thus, for example, there may be a decrease or lessening of the symptoms associated with infection. A "patient" for the purposes of the present invention includes both humans and other animals and organisms. Thus the methods are applicable to both human therapy and veterinary applications. The administration of the HAP protein as a vaccine is done in a variety of ways. Generally, the HAP proteins can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby therapeutically effective amounts of the HAP protein are combined in admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation are well known in the art. Such compositions will contain an effective amount of the HAP protein together with a suitable amount of vehicle in order to prepare pharmaceutically acceptable compositions for effective administration to the host. The composition may include salts, buffers, carrier proteins such as serum albumin, targeting molecules to localize the HAP protein at the appropriate site or tissue within the organism, and other molecules. The composition may include adjuvants as well. In one embodiment, the vaccine is administered as a single dose; that is, one dose is adequate to induce a sufficient immune response to prophylactically or therapeutically treat a Haemophilus influenzae infection. In alternate embodiments, the vaccine is administered as several doses over a period of time, as a primary vaccination and "booster" vaccinations. By "therapeutically effective amounts" herein is meant an amount of the HAP protein which is sufficient to induce an immune response. This amount may be different depending on whether prophylactic or therapeutic treatment is desired. Generally, this ranges from about 0.001 mg to about 1 gm, with a preferred range of about 0.05 to about , and the preferred dose being . These amounts may be adjusted if adjuvants are used. The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. EXAMPLES Example 1 Cloning of the HAP protein Bacterial Strains, plasmids, and phage. H. influenzae strain N187 is a clinical isolate that was originally cultivated from the middle ear fluid of a child with acute otitis media. This strain was classified as nontypable based on the absence of agglutination with typing antisera for H. influenzae types a-f (Burroughs Wellcome) and the failure to hybridize with pU038, a plasmid that contains the entire cap b locus (Kroll and Moxon, 1988, J. Bacteriol . 170:859-864) . H. influenzae strain DB117 is a reel mutant of Rd, a capsule-deficient serotype d strain that has been in the laboratory for over 40 years (Alexander and Leidy, 1951, J. Exp. Med. 83:345-359) ; DB117 was obtained from G. Barcak (University of Maryland, Baltimore, MD) (Sellow et al . , 1968) . DB117 is deficient for in vi tro adherence and invasion, as assayed below. H. influenzae strain 12 is the nontypable strain from which the genes encoding the HMW1 and HMW2 proteins were cloned (Barenkamp and Leininger, 1992, Infect. Immun. 60:1302-1313) ; HMW1 and HMW2 are the prototypic members of a family of nontypable Haemophilus antigenically- related high-molecular-weight adhesive proteins (St. Geme et al . , 1993) . E. coli HB101, which is nonadherent and noninvasive, has been previously described (Sambrook et al . , 1989, Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. ) . E. coli DH5α was obtained from Bethesda Research Laboratories. E. coli MC1061 was obtained from H. Kimsey (Tufts University, Boston, MA) . E. coli XL-1 Blue and the plasmid pBluescript KS- were obtained from Stratagene. Plasmid pT7-7 and phage mGPl-2 were provided by S. Tabor (Harvard Medical School, Boston, MA) (Tabor and Richardson, 1985, Proc. Natl . Acad. Sci. USA. 82:1074-1078) . The E. coli -Haemophilus shuttle vector pGJB103 (Tomb et al . , 1989, Rd. J. Bacteriol. 171:3796-3802) and phage X1105 (Way et al . , 1984, Gene. 32:3 69-379) were provided by G. Barcak (University of Maryland, Baltimore, MD) . Plasmid pVD116 harbors the IgAl protease gene from H. influenzae strain Rd (Koomey and Falkow, 1984, Infect. Immun. 43:101-107) and was obtained from M. Koomey (University of Michigan, Ann Arbor, MI) . Growth conditions. H. influenzae strains were grown as described (Anderson et al . , 1972, J. Clin. Invest. 51:31-38) . They were stored at -80°C in brain heart infusion broth with 25% glycerol. E. coli strains were grown on LB agar or in LB broth. They were stored at - 80°C in LB broth with 50% glycerol. For H. influenzae, tetracycline was used in a concentration of 5 μg/ml and kanamycin was used in a concentration of 25 μg/ml. For E. coli , antibiotics were used in the following concentrations: tetracycline, 12.5 μg/ml; kanamycin, 50 μg/ml; ampicillin, 100 μg/ml. Recombinant DNA methods. DNA ligations, restriction endonuclease digestions, and gel electrophoresis were performed according to standard techniques (Sambrook et al . , 1989, supra) . Plasmids were introduced into E . coli strains by either chemical transformation or electroporation, as described (Sambrook et al, 1989, supra; Dower et al . , 1988, Nucleic Acids Res. 16:617- 6145) . In H. influenzae transformation was performed using the MIV method of Herriott et al . (1970, J. Bacteriol. 101:517-524) , and electroporation was carried out using the protocol developed for E. coli (Dower et al . , 1988, supra) . Construction of genomic library from H. influenzae strain N187. High-molecular-weight chromosomal DNA was prepared from 3 ml of an overnight broth culture of H. influenzae N187 as previously described (Mekalanos, 1983, Cell. 35:253-263) . Following partial digestion with Sau3AI, 8 to 12 kb fragments were eluted into DEAE paper (Schleicher & Schuell, Keene, H.H.) and then ligated to Bglll-digested calf intestine phosphatase- treated pGJB103. The ligation mixture was electroporated into H. influenzae DB117, and transformants were selected on media containing tetracycline. Tranβposon mutagenesis. Mutagenesis of plasmid DNA was performed using the mini- TnlO kan element described by Way et al . (1984, supra) . Initially, the appropriate plasmid was introduced into E. coli MC1061. The resulting strain was infected with X1105, which carries the mini-TnlO kan transposon. Transductants were grown overnight in the presence of kanamycin and an antibiotic to select for the plasmid, and plasmid DNA was isolated using the alkaline lysis method. In order to recover plasmids containing a transposon insertion, plasmid DNA was electroporated into E. coli DH5α, plating on media containing kanamycin and the appropriate second antibiotic. ■ In order to establish more precisely the region of pN187 involved in promoting interaction with host cells, initially this plasmid was subjected to restriction endonuclease analysis. Subsequently, several subclones were constructed in the vector pGJB103 and were reintroduced into H. influenzae strain DB117. The resulting strains were then examined for adherence and invasion. As summarized in Figure 4, subclones containing either a 3.9-kb Pstl-Bglll fragment (pJS105) or the adjoining 4.2-kb Bglll fragment (pJS102) failed to confer the capacity to associate with Chang cells. In contrast, a subclone containing an insert that included portions of both of these fragments (pJS106) did promote interaction with epithelial monolayers. Transposon mutagenesis performed on pH187 confirmed that the flanking portions of the insert in this plasmid were not required for the adherent/invasive phenotype. On the other hand, a transposon insertion located adjacent to the Bglll site in pJS106 eliminated adherence and invasion. An insertion between the second EcoRl and PstI sites in this plasmid had a similar effect (Figure 4) . Examination of plasmid-encoded proteins. In order to examine plasmid encoded proteins, relevant DNA was ligated into the bacteriophage T7 expression vector pT7-7, and the resulting construct was transformed into E. coli XL-1 Blue. Plasmid pT7-7 contains the T7 phage φlO promoter and ribosomal binding site upstream of a multiple cloning site (Tabor and Richardson, 1985, supra) . The T7 promoter was induced by infection with the recombinant M13 phage mGPl-2 and addition of isopropyl-S-D-thiogalactopyranoside (final concentration, 1 mM) . Phage mGPl-2 contains the gene encoding T7 RNA polymerase, which activates the φlO promoter in pT7-7 (Tabor and Richardson, 1985, supra) . Like DB117(pN187) , strain DB117 carrying pJS106 expressed new outer membrane proteins 160-kD and 45-kD in size (Figure 3, lane 3) . In order to examine whether the 6.5-kb insert in pJS106 actually encodes these proteins, this fragment of DNA was ligated into the bacteriophage T7 expression vector pT7-7. The resulting plasmid containing the insert in the same orientation as in pN187 was designated pJS104, and the plasmid with the insert in the opposite orientation was designated pJS103. Both pJS104, and p7S103 were introduced into E. coli XL-1 Blue, producing XL-1 Blue(pJS104) and XL-1 Blue (pJS103) , respectively. As a negative control, pT7- 7 was also transformed into XL-1 Blue. The T7 promoter was induced in these three strains by infection with the recombinant M13 phage mGPl-2 and addition of isopropyl- jβ-D-thiogalactopyranoside (final concentration, 1 mM) , and induced proteins were detected using [ 35 5] methionine. As shown in Figure 5, induction of XL-1 Blue (pJS104) resulted in expression of a 160-kD protein and several smaller proteins which presumably represent degradation products. In contrast, when XL-1 Blue (pJS103) and XL-1 Blue(pT7-7) were induced, there was no expression of these proteins. There was no 45-kD protein induced in any of the three strains. This experiment suggested that the 6.5-kb insert present in pJS106 contains the structural gene for the 160-kD outer membrane protein identified in DB117 (pJS106) . On the other hand, this analysis failed to establish the origin of the 45-kD membrane protein expressed by DB117 (pJS106) . Adherence and invasion assays. Adherence and invasion assays were performed with Chang epithelial cells [Wong-Kilbourne derivative, clone l-5c- 4 (human conjunctiva)] , which were seeded into wells of 24-well tissue culture plates as previously described (St. Geme and Falkow, 1990) . Adherence was measured after incubating bacteria with epithelial monolayers for 30 minutes as described (St. Geme et al . , 1993) . Invasion assays were carried out according to our original protocol and involved incubating bacteria with epithelial cells for four hours followed by treatment with gentamicin for two hours (100 μg/ml) (St. Geme and Falkow, 1990) . Nucleotide sequence determination and analysis. Nucleotide sequence was determined using a Sequenase kit and double stranded plasmid template. DNA fragments were subcloned into pBluescript KS " and sequenced along both strands by primer walking. DNA sequence analysis was performed using the Genetics Computer Group (GCG) software package from the University of Wisconsin (Devereux et al . , 1984) . Sequence similarity searches were carried out using the BLAST program of the National Center for Biotechnology Information (Altschul et al . , 1990, J. Mol. Biol. 215:403-410) . The DNA sequence described here will be deposited in the EMBL/GenBank/DDBJ Nucleotide Sequence Data Libraries. Based on the our subcloning results, we reasoned that the central Bglll site in pH187 was positioned within an open reading frame. Examination of a series of mini- TnlO kan mutants supported this conclusion (Figure 4) . Consequently, we sequenced DHA on either side of this Bglll site and identified a 4182 bp gene, which we have designated hap for Haemophil us adherence and penetration (Figure 6) . This gene encodes a 1394 amino acid polypeptide, which we have called Hap, with a calculated molecular mass of 155.4-kD, in good agreement with the molecular mass of the larger of the two novel outer membrane proteins expressed by DB117 (pNII 87) and the protein expressed after induction of XL-1 Blue/pJS104. The hap gene has a G+C content of 39.1%, similar to the published estimate of 38.7% for the whole genome (Kilian, 1976, J. Gen. Microbiol. 93:9-62) . Putative - 10 and -35 promoter sequences are present upstream of the initiation codon. A consensus ribosomal binding site is lacking. A sequence similar to a rho- independent transcription terminator is present beginning 39 nucleotides beyond the stop codon and contains interrupted inverted repeats with the potential for forming a hairpin structure containing a loop of three bases and a stem of eight bases. Similar to the situation with typical E. coli terminators, this structure is followed by a stretch rich in T residues. Analysis of the predicted amino acid sequence suggested the presence of a 25 amino acid signal peptide at the amino terminus. This region has characteristics typical of procaryotic signal peptides, with three positive H- terminal charges, a central hydrophobic region, and alanine residues at positions 23 and 25 (-3 and -1 relative to the putative cleavage site) (von Heijne, 1984, J. Mol. Biol. 173:243-251) . Comparison of the deduced amino acid sequence of Hap with other proteins. A protein sequence similarity search was performed with the predicted amino acid sequence using the BLAST network service of the National Center for Biotechnology Information (Altschul et al . , 1990, supra) . This search revealed homology with the IgAl proteases of H. influenzae and Neisseria gonorrhoeae . Alignment of the derived amino acid sequences for the hap gene product and the IgAl proteases from four different H. influenzae strains revealed homology across the extent of the proteins (Figure 7) , with several stretches showing 55-60% identity and 70-80% similarity. Similar levels of homology were noted between the hap product and the IgAl protease from iV. gonorrhoeae strain MS11. This homology includes the region identified as the catalytic site of the IgAl proteases, which is comprised of the sequence GDSGSPLF, where 2 is the active site serine characteristic of serine proteases (Brenner, 1988, Nature (London) . 334:528-530; Poulsen et al . , 1992, J. Bacteriol. 174:2913-2921) . In the case of Hap, the corresponding sequence is GDSGSPMF. The hap product also contains two cysteines corresponding to the cysteines proposed to be important in forming the catalytic domain of the IgA proteases (Pohlner et al . , 1987, supra) . Overall there is 30-35% identity and 51- 55% similarity between the hap gene product and the H. influenzae and N. gonorrhoeae IgA proteases. The deduced amino acid sequence encoded by hap was also found to contain significant homology to Tsh, a hemagglutinin expressed by an avian E. coli strain (Provence and Curtiss, 1994, supra) . This homology extends throughout both proteins but is greatest in the H-terminal half of each. Overall the two proteins are 30.5% identical and 51.6% similar. Tsh is also synthesized as a preprotein and is secreted as a smaller form; like the IgAl proteases and perhaps Hap, a carboxy terminal peptide remains associated with the outer membrane (D. Provence, personal communication) . While this protein is presumed to have proteolytic activity, its substrate has not yet been determined. Interestingly, Tsh was first identified on the basis of its capacity to promote agglutination of erythrocytes . Thus Hap and Tsh are possibly the first members of a novel class of adhesive proteins that are processed analogously to the IgAl proteases. Homology was also noted with pertactin, a 69-kD outer membrane protein expressed by B. pertussis (Charles et al . , 1989, Proc. Natl. Acad. Sci. USA. 86:3554-3558) . The middle portions of these two molecules are 39% identical and nearly 60% similar. This protein contains the amino acid triplet arginine-glycine-aspartic acid (RGD) and has been shown to promote attachment to cultured mammalian cells via this sequence (Leininger et al., 1991, Proc. Natl. Acad. Sci. USA. 88:345-349) . Although Bordetella species are not generally considered intracellular parasites, work by Ewanowich and coworkers indicates that these respiratory pathogens are capable of in vi tro entry into human epithelial cells (Ewanowich et al., 1989, Infect. Immun. 57:2698-2704; Ewanowich et al . , 1989, Infect. Immun. 57:1240-1247) . Recently Leininger et al . reported that preincubation of epithelial monolayers with an RGD-containing peptide derived from the pertactin sequence specifically inhibited B. pertussis entry (Leininger et al . , 1992, Infect. Immun. 60:2380-2385) . In addition, these investigators found that coating of Staphylococcus aureuε with purified pertactin resulted in more efficient S. aureus entry; the RGD-containing peptide from pertactin inhibited this pertactin-enhanced entry by 75%. Although the hap product lacks an RGD motif, it is possible that Hap and pertactin serve similar biologic functions for H. influenzae and Bordetella species, respectively. Additional analysis revealed significant homology (34 to 52% identity, 42 to 70% similarity) with six regions of HpmA, a calcium-independent hemolysin expressed by Proteus mirabilis (Uphoff and Welch, 1990, supra) . The hap locus is distinct from the H. influenzae IgAl protease gene. Given the degree of similarity between the hap gene product and H. influenzae IgAl protease, we wondered whether we had isolated the IgAl protease gene of strain N187. To examine this possibility, we performed IgAl protease activity assays. Among H. influenzae strains, two enzymatically distinct types of IgAl protease have been found (Mulks et al., 1982, J. Infect. Dis. 146:266- 274) . Type 1 enzymes cleave the Pro-Ser peptide bond between residues 231 and 232 in the hinge region of human IgAl heavy chain and generate fragments of roughly 28-kD and 31-kD; type 2 enzymes cleave the Pro-Thr bond between residues 235 and 236 in the hinge region and generate 26.5-kD and 32.5-kD fragments. Previous studies of the parent strain from which DB117 was derived have demonstrated that this strain produces a type 1 IgAl protease (Koomey and Falkow, 1984, supra) . As shown in Figure 8, comparison of the proteolytic activities of strain DB117 and strain N187 suggested that N187 produces a type 2 IgAl protease. We reasoned that DB117(pN187) might generate a total of four fragments from IgAl protease, consistent with two distinct cleavage specificities. Examination of DB117(pH187) revealed instead that this transformant produces the same two fragments of the IgAl heavy chain as does DB117, arguing that this strain produces only a type 1 enzyme. In an effort to obtain additional evidence against the possibility that plasmid pH187 contains the N187 IgAl protease gene, we performed a series of Southern blots. As shown in Figure 9, when genomic DNA from strain N187 was digested with BcoRI, Bglll, or BamHI and then probed with the hap gene, one set of hybridizing fragments was detected. Probing of the same DNA with the iga gene from H. influenzae strain Rd resulted in a different set of hybridizing bands. Moreover, the iga gene failed to hybridize with a purified 4.8-kb fragment that contained the intact hap gene. The recombinant plasmid associated with adherence and invasion encodes a secreted protein. The striking homology between the hap gene product and the Haemophilus and Neiεseria IgAl proteases suggested the possibility that these proteins might be processed in a similar manner. The IgAl proteases are synthesized as preproteins with three functional domains: the N- terminal signal peptide, the protease, and a C-terminal helper domain, which is postulated to form a pore in the outer membrane for secretion of the protease (Poulsen et al . , 1989, supra; Pohlner et al. , 1987, supra) . The C-terminal peptide remains associated with the outer membrane following an autoproteolytic cleavage event that results in release of the mature enzyme. Consistent with the possibility that the hap gene product follows a similar fate, we found that DB117(pN187) produced a secreted protein approximately 110-kD in size that was absent from DB117 (pGJB103) (Figure 10) . This protein was also produced by DB117(pJS106) , but not by DB117 (pJ5102) or DB117 (pJS105) . Furthermore, the two mutants with transposon insertions within the hap coding region were deficient in this protein. In order to determine the relationship between hap and the secreted protein, this protein was transferred to a PVDF membrane and N- terminal amino acid sequencing was performed. Excessive background on the first cycle precluded identification of the first amino acid residue of the free amino terminus. The sequence of the subsequent seven residues was found to be HTYFGID, which corresponds to amino acids 27 through 33 of the hap product. The introduction of hap into laboratory strains of E. coli strains was unable to endow these organisms with the capacity for adherence or invasion. In considering these results, it is noteworthy that the E. coli transformants failed to express either the 160-kD or the 45-kD outer membrane protein. Accordingly, they also failed to express the 110-kD secreted protein. The explanation for this lack of expression is unclear. One possibility is that the H. influenzae promoter or ribosomal binding site was poorly recognized in E. coli . Indeed the putative -35 sequence upstream of the hap initiation codon is fairly divergent from the σ70 consensus sequence, and the ribosomal binding site is unrecognizable. Alternatively, an accessory gene may be required for proper export of the Hap protein, although the striking homology with the IgA proteases, which are normally expressed and secreted in E. coli , argues against this hypothesis. In considering the possibility that the hap gene product promotes adherence and invasion by directly binding to a host cell surface structure, it seems curious that the mature protein is secreted from the organism. However, there are examples of other adherence factors that are also secreted. Filamentous hemagglutinin is a 220-kD protein expressed by B . pertussis that mediates in vi tro adherence and facilitates natural colonization (Relman et al . , 1989, Proc. Natl. Acad. Sci. U.S.A. 86:2637- 2641; Kimura et al . , 1990, Infect. Immun. 58:7-16) . This protein remains surface-associated to some extent but is also released from the cell . The process of Filamentous hemagglutinin secretion involves an accessory protein designated FhaC, which appears to be localized to the outer membrane (Willems et al . , 1994, Molec. Microbiol. 11:337-347) . Similarly, the Ipa proteins implicated in Shigella invasion are also secreted. Secretion of these proteins requires the products of multiple genes within the mxi and spa loci (Allaoui et al . , 1993, Molec. Microbiol. 7:59-68; Andrews et al . , 1991, Infect. Immun. 59:1997-2005; Venkatsan et al . , 1992, J. Bacteriol. 174:1990-2001) . It is conceivable that secretion is simply a consequence of the mechanism for export of the hap gene product to the surface of the organism. However, it is noteworthy that the secreted protein contains a serine-type protease catalytic domain and shows homology with the P. mirobilis hemolysin. These findings suggest that the mature Hap protein may possess proteolytic activity and raise the possibility that Hap promotes interaction with the host cell at a distance by modifying the host cell surface. Alternatively, Hap may modify the bacterial surface in order to facilitate interaction with a host cell receptor. It is possible that hap encodes a molecule with dual functions, serving as both adhesin and protease. Analysis of outer membrane and secreted proteins. Outer membrane proteins were isolated on the basis of sarcosyl insolubility according to the method of Carlone et al. (1986, J. Clin. Microbiol. 24:330-332) . Secreted proteins were isolated by centrifuging bacterial cultures at 16,000 g for 10 minutes, recovering the supernatant, and precipitating with trichloroacetic acid in a final concentration of 10%. SDS-polyacrylamide gel electrophoresis was performed as previously described (Laemmli, 1970, Nature (London) . 227:680-685) . To identify proteins that might be involved in the interaction with the host cell surface, outer membrane protein profiles for DB117(pN187) and DB117 (pGJB103) were compared. As shown in Figure 3, DB117(pN187) expressed two new outer membrane proteins: a high- molecular-weight protein approximately 160-kD in size and a 45-kD protein. E. coli HB101 harboring pN187 failed to express these proteins, suggesting an explanation for the observation that HB101(pN187) is incapable of adherence or invasion. Previous studies have demonstrated that a family of antigenically-related high-molecular-weight proteins with similarity to filamentous hemagglutinin of Bordetella pertussis mediate attachment by nontypable H. influenzae to cultured epithelial cells (St. Geme et al . , 1993) . To explore the possibility that the gene encoding the strain H187 member of this family was cloned, whole cell lysates of N187, DB117 (pN187) , and DB117 (pGJB103) were examined by Western immunoblot. Our control strain for this experiment was H. influenzae strain 12. Using a polyclonal antiserum directed against HMW1 and HMW2, the prototypic proteins in this family, we identified a 140-kD protein in strain H187 (not shown) . In contrast, this antiserum failed to react with either DB117(pN187) or DB117 (pGJB103) (not shown) , indicating that pN187 has no relationship to HMW protein expression. Determination of amino terminal sequence. Secreted proteins were precipitated with trichloroacetic acid, separated on a 10% SDS-polyacrylamide gel, and electrotransferred to a polyvinylidene difluoride (PVDF) membrane (Matsudaira, 1987, J. Biol. Chem. 262:10035- 10038) . Following staining with Coomassie Brilliant Blue R-250, the 110-kD protein was cut from the PVDF membrane and submitted to the Protein Chemistry Laboratory at Washington University School of Medicine for amino terminal sequence determination. Sequence analysis was performed by automated Edman degradation using an Applied Biosystems Model 470A protein sequencer. Examination of IgAl protease activity. In order to assess IgAl protease activity, bacteria were inoculated into broth and grown aerobically overnight. Samples were then centrifuged in a microphage for two minutes, and supernatants were collected. A 10 μl volume of supernatant was mixed with 16 μl of 0.5 μg/ml human IgAl (Calbiochem) , and chloramphenicol was added to a final concentration of 2 μg/ml. After overnight incubation at 37°C, reaction mixtures were electrophoresed on a 10% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane, and probed with goat anti-human IgAl heavy chain conjugated to alkaline phosphatase (Kirkegaard & Perry) . The membrane was developed by immersion in phosphatase substrate solution (5-bromo-4-chloro-3- indolylphosphate toluidinium-nitro blue tetrazolium substrate system; Kirkegaard & Perry) . Immunoblot analysis. Immunoblot analysis of bacterial whole cell lysates was carried out as described (St. Geme et al . , 1991) . Southern hybridization. Southern blotting was performed using high stringency conditions as previously described (St. Geme and Falkow, 1991) . Microscopy. i. Light microscopy. Samples of epithelial cells with associated bacteria were stained with Giemsa stain and examined by light microscopy as described (St. Geme and Falkow, 1990) . ii . Transmiεsion electron microscopy. For transmission electron microscopy, bacteria were incubated with epithelial cell monolayers for four hours and were then rinsed four times with PBS, fixed with 2% glutaraldehyde/1% osmium tetroxide in 0.1 M sodium phosphate buffer pH 6.4 for two hours on ice, and stained with 0.25% aqueous uranyl acetate overnight. Samples were then dehydrated in graded ethanol solutions and embedded in polybed. Ultrathin sections (0.4 μm) were examined in a Phillips 201c electron microscope. As shown in Figure 2, DB117(pN187) incubated with monolayers for four hours demonstrated intimate interaction with the epithelial cell surface and was occasionally found to be intracellular. In a given thin section, invaded cells generally contained one or two intracellular organisms. Of note, intracellular bacteria were more common in sections prepared with strain N187, an observation consistent with results using the gentamicin assay. In contrast, examination of samples prepared with strain DB117 carrying cloning vector alone (pGJB103) failed to reveal internalized bacteria (not shown) . Having described the preferred embodiments of the present invention it will appear to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments, and that such modifications are intended to be within the scope of the present invention. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Washington University, et al. (ii) TITLE OF INVENTION: Haemophilus Adherence and Penetration Protein (iii) NUMBER OF SEQUENCES: 9 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Flehr, Hohbach, Test, Albritton & Herbert (B) STREET: 4 Embarcadero Center, Suite 3400 (C) CITY: San Francisco (D) STATE: California (E) COUNTRY: United States (F) ZIP: 94111-4187 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS <D) SOFTWARE: Patentln Release #1.0, Version #1.25 <vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: PCT/US95/ (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/296,791 (B) FILING DATE: 25 AUG 1994 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Trecartin, Richard F. (B) REGISTRATION NUMBER: 31,801 (C) REFERENCE/DOCKET NUMBER: FP-59941/RFT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (415) 781-1989 (B) TELEFAX: (415) 398-3249 (C) TELEX: 910 277299 (2) INFORMATION FOR SEQ ID NO:1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4319 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: both (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 60..4241 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 : TCAATAGTCG TTTAACTAGT ATTTTTTAAT ACGAAAAATT ACTTAATTAA ATAAACATT 59 ATG AAA AAA ACT GTA TTT CGT CTT AAT TTT TTA ACC GCT TGC ATT TCA 107 Met Lys Lys Thr Val Phe Arg Leu Asn Phe Leu Thr Ala Cys He Ser 1 5 10 15 TTA GGG ATA GTA TCG CAA GCG TGG GCT GGT CAC ACT TAT TTT GGG ATT 155 Leu Gly He Val Ser Gin Ala Trp Ala Gly His Thr Tyr Phe Gly He 20 25 30 GAT TAC CAA TAT TAT CGT GAT TTT GCC GAG AAT AAA GGG AAG TTC ACA 203 Asp Tyr Gin Tyr Tyr Arg Asp Phe Ala Glu Asn Lys Gly Lys Phe Thr 35 40 45 GTT GGG GCT CAA AAT ATT AAG GTT TAT AAC AAA CAA GGG CAA TTA GTT 251 Val Gly Ala Gin Asn He Lys Val Tyr Asn Lys Gin Gly Gin Leu Val 50 55 60 GGC ACA TCA ATG ACA AAA GCC CCG ATG ATT GAT TTT TCT GTA GTG TCA 299 Gly Thr Ser Met Thr Lys Ala Pro Met He Asp Phe Ser Val Val Ser 65 70 75 80 CGT AAC GGC GTG GCA GCC TTG GTT GAA AAT CAA TAT ATT GTG AGC GTG 347 Arg Asn Gly Val Ala Ala Leu Val Glu Asn Gin Tyr He Val Ser Val 85 90 95 GCA CAT AAC GTA GGA TAT ACA GAT GTT GAT TTT GGT GCA GAG GGA AAC 35Ξ Ala His Asn Val Gly Tyr Thr Asp Val Asp Phe Gly Ala Glu Gly Asn 100 105 110 AAC CCC GAT CAA CAT CGT TTT ACT TAT AAG ATT GTA AAA CGA AAT AAC 443 Asn Pro Asp Gin His Arg Phe Thr Tyr Lys He Val Lys Arg Asn Asn 115 120 125 TAC AAA AAA GAT AAT TTA CAT CCT TAT GAG GAC GAT TAC CAT AAT CCA 491 Tyr Lys Lys Asp Asn Leu His Pro Tyr Glu Asp Asp Tyr His Asn Pro 130 135 140 CGA TTA CAT AAA TTC GTT ACA GAA GCG GCT CCA ATT GAT ATG ACT TCG 539 Arg Leu His Lys Phe Val Thr Glu Ala Ala Pro He Asp Met Thr Ser 145 150 155 160 AAT ATG AAT GGC AGT ACT TAT TCA GAT AGA ACA AAA TAT CCA GAA CGT 587 Asn Met Asn Gly Ser Thr Tyr Ser Asp Arg Thr Lys Tyr Pro Glu Arg 165 170 175 GTT CGT ATC GGC TCT GGA CGG CAG TTT TGG CGA AAT GAT CAA GAC AAA 635 Val Arg He Gly Ser Gly Arg Gin Phe Trp Arg Asn Asp Gin Asp Lys 180 185 190 GGC GAC CAA GTT GCC GGT GCA TAT CAT TAT CTG ACA GCT GGC AAT ACA 683 Gly Asp Gin Val Ala Gly Ala Tyr His Tyr Leu Thr Ala Gly Asn Thr 195 200 205 CAC AAT CAG CGT GGA GCA GGT AAT GGA TAT TCG TAT TTG GGA GGC GAT 731 His Asn Gin Arg Gly Ala Gly Asn Gly Tyr Ser Tyr Leu Gly Gly Asp 210 215 220 GTT CGT AAA GCG GGA GAA TAT GGT CCA TTA CCG ATT GCA GGC TCA AAG 779 Val Arg Lys Ala Gly Glu Tyr Gly Pro Leu Pro He Ala Gly Ser Lys 225 230 235 240 GGG GAC AGT GGT TCT CCG ATG TTT ATT TAT GAT GCT GAA AAA CAA AAA 827 Gly Asp Ser Gly Ser Pro Met Phe He Tyr Asp Ala Glu Lys Gin Lys 245 250 255 TGG TTA ATT AAT GGG ATA TTA CGG GAA GGC AAC CCT TTT GAA GGC AAA 875 Trp Leu He Asn Gly He Leu Arg Glu Gly Asn Pro Phe Glu Gly Lys 260 265 270 GAA AAT GGG TTT CAA TTG GTT CGC AAA TCT TAT TTT GAT GAA ATT TTC 923 Glu Asn Gly Phe Gin Leu Val Arg Lys Ser Tyr Phe Asp Glu He Phe 275 280 285 GAA AGA GAT TTA CAT ACA TCA CTT TAC ACC CGA GCT GGT AAT GGA GTG 971 Glu Arg Asp Leu His Thr Ser Leu Tyr Thr Arg Ala Gly Asn Gly Val 290 295 300 TAC ACA ATT AGT GGA AAT GAT AAT GGT CAG GGG TCT ATA ACT CAG AAA 1019 Tyr Thr He Ser Gly Asn Asp Asn Gly Gin Gly Ser He Thr Gin Lys 305 310 315 320 TCA GGA ATA CCA TCA GAA ATT AAA ATT ACG TTA GCA AAT ATG AGT TTA 1067 Ser Gly He Pro Ser Glu He Lys He Thr Leu Ala Asn Met Ser Leu 325 330 335 CCT TTG AAA GAG AAG GAT AAA GTT CAT AAT CCT AGA TAT GAC GGA CCT 1115 Pro Leu Lys Glu Lys Asp Lys Val His Asn Pro Arg Tyr Asp Gly Pro 340 345 350 AAT ATT TAT TCT CCA CGT TTA AAC AAT GGA GAA ACG CTA TAT TTT ATG 1163 Asn He Tyr Ser Pro Arg Leu Asn Asn Gly Glu Thr Leu Tyr Phe Met 355 360 365 GAT CAA AAA CAA GGA TCA TTA ATC TTC GCA TCT GAC ATT AAC CAA GGG 1211 Asp Gin Lys Gin Gly Ser Leu He Phe Ala Ser Asp He Asn Gin Gly 370 375 380 GCG GGT GGT CTT TAT TTT GAG GGT AAT TTT ACA GTA TCT CCA AAT TCT 1259 Ala Gly Gly Leu Tyr Phe Glu Gly Asn Phe Thr Val Ser Pro Asn Ser 385 390 395 400 AAC CAA ACT TGG CAA GGA GCT GGC ATA CAT GTA AGT GAA AAT AGC ACC 1307 Asn Gin Thr Trp Gin Gly Ala Gly He His Val Ser Glu Asn Ser Thr 405 410 415 GTT ACT TGG AAA GTA AAT GGC GTG GAA CAT GAT CGA CTT TCT AAA ATT 1355 Val Thr Trp Lys Val Asn Gly Val Glu His Asp Arg Leu Ser Lys He 420 425 430 GGT AAA GGA ACA TTG CAC GTT CAA GCC AAA GGG GAA AAT AAA GGT TCG 1403 Gly Lys Gly Thr Leu His Val Gin Ala Lys Gly Glu Asn Lys Gly Ser 435 440 445 ATC AGC GTA GGC GAT GGT AAA GTC ATT TTG GAG CAG CAG GCA GAC GAT 1451 He Ser Val Gly Asp Gly Lys Val He Leu Glu Gin Gin Ala Asp Asp 450 455 460 CAA GGC AAC AAA CAA GCC TTT AGT GAA ATT GGC TTG GTT AGC GGC AGA 1499 Gin Gly Asn Lys Gin Ala Phe Ser Glu He Gly Leu Val Ser Gly Arg 465 470 475 480 GGG ACT GTT CAA TTA AAC GAT GAT AAA CAA TTT GAT ACC GAT AAA TTT 1547 Gly Thr Val Gin Leu Asn Asp Asp Lys Gin Phe Asp Thr Asp Lys Phe 485 490 495 TAT TTC GGC TTT CGT GGT GGT CGC TTA GAT CTT AAC GGG CAT TCA TTA 1595 Tyr Phe Gly Phe Arg Gly Gly Arg Leu Asp Leu Asn Gly His Ser Leu 500 505 510 ACC TTT AAA CGT ATC CAA AAT ACG GAC GAG GGG GCA ATG ATT GTG AAC 1643 Thr Phe Lys Arg He Gin Asn Thr Asp Glu Gly Ala Met He Val Asn 515 520 525 CAT AAT ACA ACT CAA GCC GCT AAT GTC ACT ATT ACT GGG AAC GAA AGC 1691 His Asn Thr Thr Gin Ala Ala Asn Val Thr He Thr Gly Asn Glu Ser 530 535 540 ATT GTT CTA CCT AAT GGA AAT AAT ATT AAT AAA CTT GAT TAC AGA AAA 1739 He Val Leu Pro Asn Gly Asn Asn He Asn Lys Leu Asp Tyr Arg Lys 545 550 555 560 GAA ATT GCC TAC AAC GGT TGG TTT GGC GAA ACA GAT AAA AAT AAA CAC 1787 Glu He Ala Tyr Asn Gly Trp Phe Gly Glu Thr Asp Lys Asn Lys His 565 570 575 AAT GGG CGA TTA AAC CTT ATT TAT AAA CCA ACC ACA GAA GAT CGT ACT 1835 Asn Gly Arg Leu Asn Leu He Tyr Lys Pro Thr Thr Glu Asp Arg Thr 580 585 590 TTG CTA CTT TCA GGT GGT ACA AAT TTA AAA GGC GAT ATT ACC CAA ACA 1883 Leu Leu Leu Ser Gly Gly Thr Asn Leu Lys Gly Asp He Thr Gin Thr 595 600 605 AAA GGT AAA CTA TTT TTC AGC GGT AGA CCG ACA CCG CAC GCC TAC AAT 1931 Lys Gly Lys Leu Phe Phe Ser Gly Arg Pro Thr Pro His Ala Tyr Asn 610 615 620 CAT TTA AAT AAA CGT TGG TCA GAA ATG GAA GGT ATA CCA CAA GGC GAA 1979 His Leu Asn Lys Arg Trp Ser Glu Met Glu Gly He Pro Gin Gly Glu 625 630 635 640 ATT GTG TGG GAT CAC GAT TGG ATC AAC CGT ACA TTT AAA GCT GAA AAC 2027 He Val Trp Asp His Asp Trp He Asn Arg Thr Phe Lys Ala Glu Asn 645 650 655 TTC CAA ATT AAA GGC GGA AGT GCG GTG GTT TCT CGC AAT GTT TCT TCA 2075 Phe Gin He Lys Gly Gly Ser Ala Val Val Ser Arg Asn Val Ser Ser 660 665 670 ATT GAG GGA AAT TGG ACA GTC AGC AAT AAT GCA AAT GCC ACA TTT GGT 2123 He Glu Gly Asn Trp Thr Val Ser Asn Asn Ala Asn Ala Thr Phe Gly 675 680 685 GTT GTG CCA AAT CAA CAA AAT ACC ATT TGC ACG CGT TCA GAT TGG ACA 2171 Val Val Pro Asn Gin Gin Asn Thr He Cys Thr Arg Ser Asp Trp Thr 690 695 700 GGA TTA ACG ACT TGT CAA AAA GTG GAT TTA ACC GAT ACA AAA GTT ATT 2219 Gly Leu Thr Thr Cys Gin Lys Val Asp Leu Thr Asp Thr Lys Val He 705 710 715 720 AAT TCT ATA CCA AAA ACA CAA ATC AAT GGC TCT ATT AAT TTA ACT GAT 2267 Asn Ser He Pro Lys Thr Gin He Asn Gly Ser He Asn Leu Thr Asp 725 730 735 AAT GCA ACG GCG AAT GTT AAA GGT TTA GCA AAA CTT AAT GGC AAT GTC 2315 Asn Ala Thr Ala Asn Val Lys Gly Leu Ala Lys Leu Asn Gly Asn Val 740 745 750 ACT TTA ACA AAT CAC AGC CAA TTT ACA TTA AGC AAC AAT GCC ACC CAA 2363 Thr Leu Thr Asn His Ser Gin Phe Thr Leu Ser Asn Asn Ala Thr Gin 755 760 765 ATA GGC AAT ATT CGA CTT TCC GAC AAT TCA ACT GCA ACG GTG GAT AAT 2 11 He Gly Asn He Arg Leu Ser Asp Asn Ser Thr Ala Thr Val Asp Asn 770 775 780 GCA AAC TTG AAC GGT AAT GTG CAT TTA ACG GAT TCA GCT CAA TTT TCT 2459 Ala Asn Leu Asn Gly Asn Val His Leu Thr Asp Ser Ala Gin Phe Ser 785 790 795 800 TTA AAA AAC AGC CAT TTT TCG CAC CAA ATT CAG GGA GAC AAA GGC ACA 2507 Leu Lys Asn Ser His Phe Ser His Gin He Gin Gly Asp Lys Gly Thr 805 810 815 ACA GTG ACG TTG GAA AAT GCG ACT TGG ACA ATG CCT AGC GAT ACT ACA 2555 Thr Val Thr Leu Glu Asn Ala Thr Trp Thr Met Pro Ser Asp Thr Thr 820 825 830 TTG CAG AAT TTA ACG CTA AAT AAC AGT ACG ATC ACG TTA AAT TCA GCT 2603 Leu Gin Asn Leu Thr Leu Asn Asn Ser Thr He Thr Leu Asn Ser Ala 835 840 845 TAT TCA GCT AGC TCA AAC AAT ACG CCA CGT CGC CGT TCA TTA GAG ACG 2651 Tyr Ser Ala Ser Ser Asn Asn Thr Pro Arg Arg Arg Ser Leu Glu Thr 850 855 860 GAA ACA ACG CCA ACA TCG GCA GAA CAT CGT TTC AAC ACA TTG ACA GTA 269S- Glu Thr Thr Pro Thr Ser Ala Glu His Arg Phe Asn Thr Leu Thr Val 865 870 875 880 AAT GGT AAA TTG AGT GGG CAA GGC ACA TTC CAA TTT ACT TCA TCT TTA 2747 Asn Gly Lys Leu Ser Gly Gin Gly Thr Phe Gin Phe Thr Ser Ser Leu 885 890 895 TTT GGC TAT AAA AGC GAT AAA TTA AAA TTA TCC AAT GAC GCT GAG GGC 2795 Phe Gly Tyr Lys Ser Asp Lys Leu Lys Leu Ser Asn Asp Ala Glu Gly 900 905 910 GAT TAC ATA TTA TCT GTT CGC AAC ACA GGC AAA GAA CCC GAA ACC CTT 2843 Asp Tyr He Leu Ser Val Arg Asn Thr Gly Lys Glu Pro Glu Thr Leu 915 920 925 GAG CAA TTA ACT TTG GTT GAA AGC AAA GAT AAT CAA CCG TTA TCA GAT 2891 Glu Gin Leu Thr Leu Val Glu Ser Lys Asp Asn Gin Pro Leu Ser Asp 930 935 940 AAG CTC AAA TTT ACT TTA GAA AAT GAC CAC GTT GAT GCA GGT GCA TTA 2939 Lys Leu Lys Phe Thr Leu Glu Asn Asp His Val Asp Ala Gly Ala Leu 945 950 955 960 CGT TAT AAA TTA GTG AAG AAT GAT GGC GAA TTC CGC TTG CAT AAC CCA 2987 Arg Tyr Lys Leu Val Lys Asn Asp Gly Glu Phe Arg Leu His Asn Pro 965 970 975 ATA AAA GAG CAG GAA TTG CAC AAT GAT TTA GTA AGA GCA GAG CAA GCA 3035 He Lys Glu Gin Glu Leu His Asn Asp Leu Val Arg Ala Glu Gin Ala 980 985 990 GAA CGA ACA TTA GAA GCC AAA CAA GTT GAA CCG ACT GCT AAA ACA CAA 3083 Glu Arg Thr Leu Glu Ala Lys Gin Val Glu Pro Thr Ala Lys Thr Gin 995 1000 1005 ACA GGT GAG CCA AAA GTG CGG TCA AGA AGA GCA GCG AGA GCA GCG TTT 3131 Thr Gly Glu Pro Lys Val Arg Ser Arg Arg Ala Ala Arg Ala Ala Phe 1010 1015 1020 CCT GAT ACC CTG CCT GAT CAA AGC CTG TTA AAC GCA TTA GAA GCC AAA 3179 Pro Asp Thr Leu Pro Asp Gin Ser Leu Leu Asn Ala Leu Glu Ala Lys 1025 1030 1035 1040 CAA GCT GAA CTG ACT GCT GAA ACA CAA AAA AGT AAG GCA AAA ACA AAA 3227 Gin Ala Glu Leu Thr Ala Glu Thr Gin Lys Ser Lys Ala Lys Thr Lys 1045 1050 1055 AAA GTG CGG TCA AAA AGA GCA GTG TTT TCT GAT CCC CTG CTT GAT CAA 3275 Lys Val Arg Ser Lys Arg Ala Val Phe Ser Asp Pro Leu Leu Asp Gin 1060 1065 1070 AGC CTG TTC GCA TTA GAA GCC GCA CTT GAG GTT ATT GAT GCC CCA CAG 3323 Ser Leu Phe Ala Leu Glu Ala Ala Leu Glu Val He Asp Ala Pro Gin 1075 1080 1085 CAA TCG GAA AAA GAT CGT CTA GCT CAA GAA GAA GCG GAA AAA CAA CGC 3371 Gin Ser Glu Lys Asp Arg Leu Ala Gin Glu Glu Ala Glu Lys Gin Arg 1090 1095 1100 AAA CAA AAA GAC TTG ATC AGC CGT TAT TCA AAT AGT GCG TTA TCA GAA 3419 Lys Gin Lys Asp Leu He Ser Arg Tyi Ser Asn Ser Ala Leu Ser Glu 1105 1110 1115 1120 TTA TCT GCA ACA GTA AAT AGT ATG CTT TCT GTT CAA GAT GAA TTA GAT 3467 Leu Ser Ala Thr Val Asn Ser Met Leu Ser Val Gin Asp Glu Leu Asp 1125 1130 1135 CGT CTT TTT GTA GAT CAA GCA CAA TCT GCC GTG TGG ACA AAT ATC GCA 3515 Arg Leu Phe Val Asp Gin Ala Gin Ser Ala Val Trp Thr Asn He Ala 1140 1145 1150 CAG GAT AAA AGA CGC TAT GAT TCT GAT GCG TTC CGT GCT TAT CAG CAG 3563 Gin Asp Lys Arg Arg Tyr Asp Ser Asp Ala Phe Arg Ala Tyr Gin Gin 1155 1160 1165 CAG AAA ACG AAC TTA CGT CAA ATT GGG GTG CAA AAA GCC TTA GCT AAT 3611 Gin Lys Thr Asn Leu Arg Gin He Gly Val Gin Lys Ala Leu Ala Asn 1170 1175 1180 GGA CGA ATT GGG GCA GTT TTC TCG CAT AGC CGT TCA GAT AAT ACC TTT 3659 Gly Arg He Gly Ala Val Phe Ser His Ser Arg Ser Asp Asn Thr Phe 1185 1190 1195 1200 GAT GAA CAG GTT AAA AAT CAC GCG ACA TTA ACG ATG ATG TCG GGT TTT 3707 Asp Glu Gin Val Lys Asn His Ala Thr Leu Thr Met Met Ser Gly Phe 1205 1210 1215 GCC CAA TAT CAA TGG GGC GAT TTA CAA TTT GGT GTA AAC GTG GGA ACG 3755 Ala Gin Tyr Gin Trp Gly Asp Leu Gin Phe Gly Val Asn Val Gly Thr 1220 1225 1230 GGA ATC AGT GCG AGT AAA ATG GCT GAA GAA CAA AGC CGA AAA ATT CAT 3803 Gly He Ser Ala Ser Lys Met Ala Glu Glu Gin Ser Arg Lys He His 1235 1240 1245 CGA AAA GCG ATA AAT TAT GGC GTG AAT GCA AGT TAT CAG TTC CGT TTA 3851 Arg Lys Ala He Asn Tyr Gly Val Asn Ala Ser Tyr Gin Phe Arg Leu 1250 1255 1260 GGG CAA TTG GGC ATT CAG CCT TAT TTT GGA GTT AAT CGC TAT TTT ATT 3899 Gly Gin Leu Gly He Gin Pro Tyr Phe Gly Val Asn Arg Tyr Phe He 1265 1270 1275 1280 GAA CGT GAA AAT TAT CAA TCT GAG GAA GTG AGA GTG AAA ACG CCT AGC 3947 Glu Arg Glu Asn Tyr Gin Ser Glu Glu Val Arg Val Lys Thr Pro Ser 1285 1290 1295 CTT GCA TTT AAT CGC TAT AAT GCT GGC ATT CGA GTT GAT TAT ACA TTT 3995 Leu Ala Phe Asn Arg Tyr Asn Ala Gly He Arg Val Asp Tyr Thr Phe 1300 1305 1310 ACT CCG ACA GAT AAT ATC AGC GTT AAG CCT TAT TTC TTC GTC AAT TAT 4043 Thr Pro Thr Asp Asn He Ser Val Lys Pro Tyr Phe Phe Val Asn Tyr 1315 1320 1325 GTT GAT GTT TCA AAC GCT AAC GTA CAA ACC ACG GTA AAT CTC ACG GTG 4091 Val Asp Val Ser Asn Ala Asn Val Gin Thr Thr Val Asn Leu Thr Val 1330 1335 1340 TTG CAA CAA CCA TTT GGA CGT TAT TGG CAA AAA GAA GTG GGA TTA AAG 4139 Leu Gin Gin Pro Phe Gly Arg Tyr Trp Gin Lys Glu Val Gly Leu Lys 1345 1350 1355 1360 GCA GAA ATT TTA CAT TTC CAA ATT TCC GCT TTT ATC TCA AAA TCT CAA 4187 Ala Glu He Leu His Phe Gin He Ser Ala Phe He Ser Lys Ser Gin 1365 1370 1375 GGT TCA CAA CTC GGC AAA CAG CAA AAT GTG GGC GTG AAA TTG GGC TAT 23- Gly Ser Gin Leu Gly Lys Gin Gin Asn Val Gly Val Lys Leu Gly Tyr 1380 1385 1390 CGT TGG TAAAAATCAA CATAATTTTA TCGTTTATTG ATAAACAAGG TGGGTCAGAT 4291 Arg Trp CAGATCCCAC CTTTTTTATT CCAATAAT 4319 (2) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1394 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : Met Lys Lys Thr Val Phe Arg Leu Asn Phe Leu Thr Ala Cys He Ser 1 5 10 15 Leu Gly He Val Ser Gin Ala Trp Ala Gly His Thr Tyr Phe Gly He 20 25 30 Asp Tyr Gin Tyr Tyr Arg Asp Phe Ala Glu Asn Lys Gly Lys Phe Thr 35 40 45 Val Gly Ala Gin Asn He Lys Val Tyr Asn Lys Gin Gly Gin Leu Val 50 55 60 Gly Thr Ser Met Thr Lys Ala Pro Met He Asp Phe Ser Val Val Ser 65 70 75 80 Arg Asn Gly Val Ala Ala Leu Val Glu Asn Gin Tyr He Val Ser Val 85 90 95 Ala His Asn Val Gly Tyr Thr Asp Val Asp Phe Gly Ala Glu Gly Asn 100 105 110 Asn Pro Asp Gin His Arg Phe Thr Tyr Lys He Val Lys Arg Asn Asn 115 120 125 Tyr Lys Lys Asp Asn Leu His Pro Tyr Glu Asp Asp Tyr His Asn Pro 130 135 140 Arg Leu His Lys Phe Val Thr Glu Ala Ala Pro He Asp Met Thr Ser 145 150 155 160 Asn Met Asn Gly Ser Thr Tyr Ser Asp Arg Thr Lys Tyr Pro Glu Arg 165 170 175 Val Arg He Gly Ser Gly Arg Gin Phe Trp Arg Asn Asp Gin Asp Lys 180 185 " 190 Gly Asp Gin Val Ala Gly Ala Tyr His Tyr Leu Thr Ala Gly Asn Thr 195 200 205 His Asn Gin Arg Gly Ala Gly Asn Gly Tyr Ser Tyr Leu Gly Gly Asp 210 215 ' 220 Val Arg Lys Ala Gly Glu Tyr Gly Pro Leu Pre He Ala Gly Ser Lys 225 230 23: 240 Gly Asp Ser Gly Ser Pro Met Phe He Tyr Asp Ala Glu Lys Gin Lys 245 250 255 Trp Leu He Asn Gly He Leu Arg Glu Gly Asn Pro Phe Glu Gly Lys 260 265 270 Glu Asn Gly Phe Gin Leu Val Arg Lys Ser Tyr Phe Asp Glu He Phe 275 280 285 Glu Arg Asp Leu His Thr Ser Leu Tyr Thr Arg Ala Gly Asn Gly Val 290 295 300 Tyr Thr He Ser Gly Asn Asp Asn Gly Gin Gly Ser He Thr Gin Lys 305 310 315 320 Ser Gly He Pro Ser Glu He Lys He Thr Leu Ala Asn Met Ser Leu 325 330 335 Pro Leu Lys Glu Lys Asp Lys Val His Asn Pro Arg Tyr Asp Gly Pro 340 345 350 Asn He Tyr Ser Pro Arg Leu Asn Asn Gly Glu Thr Leu Tyr Phe Met 355 360 365 Asp Gin Lys Gin Gly Ser Leu He Phe Ala Ser Asp He Asn Gin Gly 370 375 380 Ala Gly Gly Leu Tyr Phe Glu Gly Asn Phe Thr Val Ser Pro Asn Ser 385 390 395 400 Asn Gin Thr Trp Gin Gly Ala Gly He His Val Ser Glu Asn Ser Thr 405 410 415 Val Thr Trp Lys Val Asn Gly Val Glu His Asp Arg Leu Ser Lys He 420 425 430 Gly Lys Gly Thr Leu His Val Gin Ala Lys Gly Glu Asn Lys Gly Ser 435 440 445 He Ser Val Gly Asp Gly Lys Val He Leu Glu Gin Gin Ala Asp Asp 450 455 460 Gin Gly Asn Lys Gin Ala Phe Ser Glu He Gly Leu Val Ser Gly Arg 465 470 475 480 Gly Thr Val Gin Leu Asn Asp Asp Lys Gin Phe Asp Thr Asp Lys Phe 485 490 495 Tyr Phe Gly Phe Arg Gly Gly Arg Leu Asp Leu Asn Gly His Ser Leu 500 505 510 Thr Phe Lys Arg He Gin Asn Thr Asp Glu Gly Ala Met He Val Asn 515 520 525 His Asn Thr Thr Gin Ala Ala Asn Val Thr He Thr Gly Asn Glu Ser 530 535 540 He Val Leu Pro Asn Gly Asn Asn He Asn Lys Leu Asp Tyr Arg Lys 545 550 555 560 Glu He Ala Tyr Asn Gly Trp Phe Gly Glu Thr Asp Lys Asn Lys His 565 570 575 Asn Gly Arg Leu Asn Leu He Tyr Lys Pro Thr Thr Glu Asp Arg Thr 580 585 590 Leu Leu Leu Ser Gly Gly Thr Asn Leu Lys Gly Asp He Thr Gin Thr 595 600 605 Lys Gly Lys Leu Phe Phe Ser Gly Arg Pro Thr Pro His Ala Tyr Asn 610 615 620 His Leu Asn Lys Arg Trp Ser Glu Met Glu Gly He Pro Gin Gly Glu 625 630 635 640 He Val Trp Asp His Asp Trp He Asn Arg Thr Phe Lys Ala Glu Asn 645 650 655 Phe Gin He Lys Gly Gly Ser Ala Val Val Ser Arg Asn Val Ser Ser 660 665 670 He Glu Gly Asn Trp Thr Val Ser Asn Asn Ala Asn Ala Thr Phe Gly 675 680 685 Val Val Pro Asn Gin Gin Asn Thr He Cys Thr Arg Ser Asp Trp Thr 690 695 700 Gly Leu Thr Thr Cys Gin Lys Val Asp Leu Thr Asp Thr Lys Val He 705 710 715 720 Asn Ser He Pro Lys Thr Gin He Asn Gly Ser He Asn Leu Thr Asp 725 730 735 Asn Ala Thr Ala Asn Val Lys Gly Leu Ala Lys Leu Asn Gly Asn Val 740 745 750 Thr Leu Thr Asn His Ser Gin Phe Thr Leu Ser Asn Asn Ala Thr Gin 755 760 765 He Gly Asn He Arg Leu Ser Asp Asn Ser Thr Ala Thr Val Asp Asn 770 775 780 Ala Asn Leu Asn Gly Asn Val His Leu Thr Asp Ser Ala Gin Phe Ser 785 790 795 800 Leu Lys Asn Ser His Phe Ser His Gin He Gin Gly Asp Lys Gly Thr 805 810 815 Thr Val Thr Leu Glu Asn Ala Thr Trp Thr Met Pro Ser Asp Thr Thr 820 825 830 Leu Gin Asn Leu Thr Leu Asn Asn Ser Thr He Thr Leu Asn Ser Ala 835 840 845 Tyr Ser Ala Ser Ser Asn Asn Thr Pro Arg Arg Arg Ser Leu Glu Thr 850 855 860 Glu Thr Thr Pro Thr Ser Ala Glu His Arg Phe Asn Thr Leu Thr Val 865 870 875 880 Asn Gly Lys Leu Ser Gly Gin Gly Thr Phe Gin Phe Thr Ser Ser Leu 885 890 895 Phe Gly Tyr Lys Ser Asp Lys Leu Lys Leu Ser Asn Asp Ala Glu Gly 900 905 910 Asp Tyr He Leu Ser Val Arg Asn Thr Gly Lys Glu Pro Glu Thr Leu 915 920 925 Glu Gin Leu Thr Leu Val Glu Ser Lys Asp Asn Gin Pro Leu Ser Asp 930 935 940 Lys Leu Lys Phe Thr Leu Glu Asn Asp His Val Asp Ala Gly Ala Leu 945 950 955 960 Arg Tyr Lys Leu Val Lys Asn Asp Gly Glu Phe Arg Leu His Asn Pro 965 970 975 He Lys Glu Gin Glu Leu His Asn Asp Leu Val Arg Ala Glu Gin Ala 980 985 990 Glu Arg Thr Leu Glu Ala Lys Gin Val Glu Pro Thr Ala Lys Thr Gin 995 1000 1005 Thr Gly Glu Pro Lys Val Arg Ser Arg Arg Ala Ala Arg Ala Ala Phe 1010 1015 1020 Pro Asp Thr Leu Pro Asp Gin Ser Leu Leu Asn Ala Leu Glu Ala Lys 1025 1030 1035 1040 Gin Ala Glu Leu Thr Ala Glu Thr Gin Lys Ser Lys Ala Lys Thr Lys 1045 1050 1055 Lys Val Arg Ser Lys Arg Ala Val Phe Ser Asp Pro Leu Leu Asp Gin 1060 1065 1070 Ser Leu Phe Ala Leu Glu Ala Ala Leu Glu Val He Asp Ala Pro Gin 1075 1080 1085 Gin Ser Glu Lys Asp Arg Leu Ala Gin Glu Glu Ala Glu Lys Gin Arg 1090 1095 1100 Lys Gin Lys Asp Leu He Ser Arg Tyr Ser Asn Ser Ala Leu Ser Glu 1105 1110 1115 1120 Leu Ser Ala Thr Val Asn Ser Met Leu Ser Val Gin Asp Glu Leu Asp 1125 1130 1135 Arg Leu Phe Val Asp Gin Ala Gin Ser Ala Val Trp Thr Asn He Ala 1140 1145 1150 Gin Asp Lys Arg Arg Tyr Asp Ser Asp Ala Phe Arg Ala Tyr Gin Gin 1155 1160 1165 Gin Lys Thr Asn Leu Arg Gin He Gly Val Gin Lys Ala Leu Ala Asn 1170 1175 1180 Gly Arg He Gly Ala Val Phe Ser His Ser Arg Ser Asp Asn Thr Phe 1185 1190 1195 1200 Asp Glu Gin Val Lys Asn His Ala Thr Leu Thr Met Met Ser Gly Phe 1205 1210 1215 Ala Gin Tyr Gin Trp Gly Asp Leu Gin Phe Gly Val Asn Val Gly Thr 1220 1225 1230 Gly He Ser Ala Ser Lys Met Ala Glu Glu Gin Ser Arg Lys He His 1235 1240 1245 Arg Lys Ala He Asn Tyr Gly Val Asn Ala Ser Tyr Gin Phe Arg Leu 1250 1255 1260 Gly Gin Leu Gly He Gin Pro Tyr Phe Gly Val Asn Arg Tyr Phe He 1265 1270 1275 1280 Glu Arg Glu Asn Tyr Gin Ser Glu Glu Val Arg Val Lys Thr Pro Ser 1285 1290 I2S5 Leu Ala Phe Asn Arg Tyr Asn Ala Gly He Arg Val Asp Tyr Thr Phe 1300 1305 1310 Thr Pro Thr Asp Asn He Ser Val Lys Pro Tyr Phe Phe Val Asn Tyr 1315 1320 1325 Val Asp Val Ser Asn Ala Asn Val Gin Thr Thr Val Asn Leu Thr Val 1330 1335 1340 Leu Gin Gin Pro Phe Gly Arg Tyr Trp Gin Lys Glu Val Gly Leu Lys 1345 1350 1355 1360 Ala Glu He Leu His Phe Gin He Ser Ala Phe He Ser Lys Ser Gin 1365 1370 1375 Gly Ser Gin Leu Gly Lys Gin Gin Asn Val Gly Val Lys Leu Gly Tyr 1380 1385 1390 Arg Trp (2) INFORMATION FOR SEQ ID NO: 3 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1541 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : Met Leu Asn Lys Lys Phe Lys Leu Asn Phe He Ala Leu Thr Val Ala 1 5 10 15 Tyr Ala Leu Thr Pro Tyr Thr Glu Ala Ala Leu Val Arg Asp Asp Val 20 25 30 Asp Tyr Gin He Phe Arg Asp Phe Ala Glu Asn Lys Gly Lys Phe Ser 35 40 45 Val Gly Ala Thr Asn Val Leu Val Lys Asp Lys Asn Asn Lys Asp Leu 50 55 60 Gly Thr Ala Leu Pro Asn Gly He Pro Met He Asp Phe Ser Val Val 65 70 75 80 Asp Val Asp Lys Arg He Ala Thr Leu He Asn Pro Gin Tyr Val Val 85 90 95 Gly Val Lys His Val Ser Asn Gly Val Ser Glu Leu His Phe Gly Asn 100 105 110 Leu Asn Gly Asn Met Asn Asn Gly Asn Ala Lys Ala His Arg Asp Val 115 120 125 Ser Ser Glu Glu Asn Arg Tyr Phe Ser Val Glu Lys Asn Glu Tyr Pro 130 135 140 Thr Lys Leu Asn Gly Lys Thr Val Thr Thr Glu Asp Gin Thr Gin Lys 145 150 155 160 Arg Arg Glu Asp Tyr Tyr Met Pro Arg Leu Asp Lye Phe Val Thr Glu 165 170 175 Val Ala Pro He Glu Ala Ser Thr Ala Ser Ser Asp Ala Gly Thr Tyr 180 185 190 Asn Asp Gin Asn Lys Tyr Pro Ala Phe Val Arg Leu Gly Ser Gly Ser 195 200 205 Gin Phe He Tyr Lys Lys Gly Asp Asn Tyr Ser Leu He Leu Asn Asn 210 215 220 His Glu Val Gly Gly Asn Asn Leu Lys Leu Val Gly Asp Ala Tyr Thr 225 230 235 240 Tyr Gly He Ala Gly Thr Pro Tyr Lys Val Asn His Glu Asn Asn Gly 245 250 255 Leu He Gly Phe Gly Asn Ser Lys Glu Glu His Ser Asp Pro Lys Gly 260 265 270 He Leu Ser Gin Asp Pro Leu Thr Asn Tyr Ala Val Leu Gly Asp Ser 275 280 285 Gly Ser Pro Leu Phe Val Tyr Asp Arg Glu Lys Gly Lys Trp Leu Phe 290 295 300 Leu Gly Ser Tyr Asp Phe Trp Ala Gly Tyr Asn Lys Lys Ser Trp Gin 305 310 315 320 Glu Trp Asn He Tyr Lys Ser Gin Phe Thr Lys Asp Val Leu Asn Lys 325 330 335 Asp Ser Ala Gly Ser Leu He Glv Ser Lys Thr Asp Tyr Ser Trp Ser 340 " 345 350 Ser Asn Gly Lys Thr Ser Thr He Thr Gly Gly Glu Lys Ser Leu Asn 355 360 365 Val Asp Leu Ala Asp Gly Lys Asp Lys Pro Asn His Gly Lys Ser Val 370 375 380 Thr Phe Glu Gly Ser Gly Thr Leu Thr Leu Asn Asn Asn He Asp Gin 385 390 395 400 Gly Ala Gly Gly Leu Phe Phe Glu Gly Asp Tyr Glu Val Lys Gly Thr 405 410 415 Ser Asp Asn Thr Thr Trp Lys Gly Ala Gly Val Ser Val Ala Glu Gly 420 425 430 Lys Thr Val Thr Trp Lys Val His Asn Pro Gin Tyr Asp Arg Leu Ala 435 440 445 Lys He Gly Lys Gly Thr Leu He Val Glu Gly Thr Gly Asp Asn Lys 450 455 460 Gly Ser Leu Lys Val Gly Asp Gly Thr Val He Leu Lys Gin Gin Thr 465 470 475 480 Asn Gly Ser Gly Gin His Ala Phe Ala Ser Val Gly He Val Ser Gly 485 490 495 Arg Ser Thr Leu Val Leu Asn Asp Asp Lys Gin Val Asp Pro Asn Ser 500 505 510 He Tyr Phe Gly Phe Arg Gly Gly Arg Leu Asp Leu Asn Glv Asn Ser 515 520 Eli Leu Thr Phe Asp His He Arg Asn He Asp Asp Gly Ala Arg Leu Val 530 535 540 Asn His Asn Met Thr Asn Ala Ser Asn He Thr He Thr Gly Glu Ser 545 550 555 560 Leu He Thr Asp Pro Asn Thr He Thr Pro Tyr Asn He Asp Ala Pro 565 570 575 Asp Glu Asp Asn Pro Tyr Ala Phe Arg Arg He Lys Asp Gly Gly Gin 580 585 590 Leu Tyr Leu Asn Leu Glu Asn Tyr Thr Tyr Tyr Ala Leu Arg Lys Gly 595 600 605 Ala Ser Thr Arg Ser Glu Leu Pro Lys Asn Ser Gly Glu Ser Asn Glu 610 615 620 Asn Trp Leu Tyr Met Gly Lys Thr Ser Asp Glu Ala Lys Arg Asn Val 625 630 635 640 Met Asn His He Asn Asn Glu Arg Met Asn Gly Phe Asn Gly Tyr Phe 645 650 655 Gly Glu Glu Glu Gly Lys Asn Asn Gly Asn Leu Asn Val Thr Phe Lys 660 665 670 Gly Lys Ser Glu Gin Asn Arg Phe Leu Leu Thr Gly Gly Thr Asn Leu 675 680 685 Asn Gly Asp Leu Thr Val Glu Lys Gly Thr Leu Phe Leu Ser Gly Arg 690 695 700 Pro Thr Pro His Ala Arg Asp He Ala Gly He Ser Ser Thr Lys Lys 705 710 715 720 Asp Pro His Phe Ala Glu Asn Asn Glu Val Val Val Glu Asp Asp Trp 725 730 735 He Asn Arg Asn Phe Lys Ala Thr Thr Met Asn Val Thr Gly Asn Ala 740 745 750 Ser Leu Tyr Ser Gly Arg Asn Val Ala Asn He Thr Ser Asn He Thr 755 760 765 Ala Ser Asn Lys Ala Gin Val His He Gly Tyr Lys Thr Gly Asp Thr 770 775 780 Val Cys Val Arg Ser Asp Tyr Thr Gly Tyr Val Thr Cys Thr Thr Asp 785 790 795 800 Lys Leu Ser Asp Lys Ala Leu Asn Ser Phe Asn Pro Thr Asn Leu Arg 805 810 815 Gly Asn Val Asn Leu Thr Glu Ser Ala Asn Phe Val Leu Gly Lys Ala 820 825 830 Asn Leu Phe Gly Thr He Gin Ser Arg Gly Asn Ser Gin Val Arg Leu 835 840 845 Thr Glu Asn Ser His Trp His Leu Thr Gly Asn Ser Asp Val His Gin 850 855 860 Leu Asp Leu Ala Asn Gly His He His Leu Asn Ser Ala Asp Asn Ser 865 870 875 860 Asn Asn Val Thr Lys Tyr Asn Thr Leu Thr Val Asn Ser Leu Ser Gly 885 890 895 Asn Gly Ser Phe Tyr Tyr Leu Thr Asp Leu Ser Asn Lys Gin Gly Asp 900 905 910 Lys Val Val Val Thr Lys Ser Ala Thr Gly Asn Phe Thr Leu Gin Val 915 920 925 Ala Asp Lys Thr Gly Glu Pro Asn His Asn Glu Leu Thr Leu Phe Asp 930 935 940 Ala Ser Lys Ala Gin Arg Asp His Leu Asn Val Ser Leu Val Gly Asn 945 950 955 960 Thr Val Asp Leu Gly Ala Trp Lys Tyr Lys Leu Arg Asn Val Asn Gly 965 970 975 Arg Tyr Asp Leu Tyr Asn Pro Glu Val Glu Lys Arg Asn Gin Thr Val 980 985 990 Asp Thr Thr Asn He Thr Thr Pro Asn Asn He Gin Ala Asp Val Pro 995 1000 1005 Ser Val Pro Ser Asn Asn Glu Glu He Ala Arg Val Asp Glu Ala Pro 1010 1015 1020 Val Pro Pro Pro Ala Pro Ala Thr Pro Ser Glu Thr Thr Glu Thr Val 1025 1030 1035 1040 Ala Glu Asn Ser Lys Gin Glu Ser Lys Thr Val Glu Lys Asn Glu Gin 1045 1050 1055 Asp Ala Thr Glu Thr Thr Ala Gin Asn Arg Glu Val Ala Lys Glu Ala 1060 1065 1070 Lys Ser Asn Val Lys Ala Asn Thr Gin Thr Asn Glu Val Ala Gin Ser 1075 1080 1085 Gly Ser Glu Thr Lys Glu Thr Gin Thr Thr Glu Thr Lys Glu Thr Ala 1090 1095 1100 Thr Val Glu Lys Glu Glu Lys Ala Lys Val Glu Thr Glu Lys Thr Gin 1105 1110 1115 1120 Glu Val Pro Lys Val Thr Ser Gin Val Ser Pro Lys Gin Glu Gin Ser 1125 1130 1135 Glu Thr Val Gin Pro Gin Ala Glu Pro Ala Arg Glu Asn Asp Pro Thr 1140 1145 1150 Val Asn He Lys Glu Pro Gin Ser Gin Thr Asn Thr Thr Ala Asp Thr 1155 1160 1165 Glu Gin Pro Ala Lys Glu Thr Ser Ser Asn Val Glu Gin Pro Val Thr 1170 1175 1180 Glu Ser Thr Thr Val Asn Thr Gly Asn Ser Val Val Glu Asn Pro Glu 1185 1190 1195 1200 Asn Thr Thr Pro Ala Thr Thr Gin Pro Thr Val Asn Ser Glu Ser Ser 1205 1210 1215 Asn Lys Pro Lys Asn Arg His Arg Arg Ser Val Arg Ser Val Pro His 1220 1225 1230 Asn Val Glu Pro Ala Thr Thr Ser Ser Asn Asp Arg Ser Thr Val Ala 1235 1240 1245 Leu Cys Asp Leu Thr Ser Thr Asn Thr Asn Ala Val Leu Ser Asp Ala 1250 1255 1260 Arg Ala Lys Ala Gin Phe Val Ala Leu Asn Val Gly Lys Ala Val Ser 1265 1270 1275 1280 Gin His He Ser Gin Leu Glu Met Asn Asn Glu Gly Gin Tyr Asn Val 1285 1290 1295 Trp Val Ser Asn Thr Ser Met Asn Lys Asn Tyr Ser Ser Ser Gin Tyr 1300 1305 1310 Arg Arg Phe Ser Ser Lys Ser Thr Gin Thr Gin Leu Gly Trp Asp Gin 1315 1320 1325 Thr He Ser Asn Asn Val Gin Leu Gly Gly Val Phe Thr Tyr Val Arg 1330 1335 1340 Asn Ser Asn Asn Phe Asp Lys Ala Thr Ser Lys Asn Thr Leu Ala Gin 1345 1350 1355 1360 Val Asn Phe Tyr Ser Lys Tyr Tyr Ala Asp Asn His Trp Tyr Leu Gly 1365 1370 1375 He Asp Leu Gly Tyr Gly Lys Phe Gin Ser Lys Leu Gin Thr Asn His 1380 1385 1390 Asn Ala Lys Phe Ala Arg His Thr Ala Gin Phe Gly Leu Thr Ala Gly 1395 1400 1405 Lys Ala Phe Asn Leu Gly Asn Phe Gly He Thr Pro He Val Gly Val 1410 1415 1420 Arg Tyr Ser Tyr Leu Ser Asn Ala Asp Phe Ala Leu Asp Gin Ala Arg 1425 1430 1435 1440 He Lys Val Asn Pro He Ser Val Lys Thr Ala Phe Ala Gin Val Asp 1445 1450 1455 Leu Ser Tyr Thr Tyr His Leu Gly Glu Phe Ser Val Thr Pro He Leu 1460 1465 1470 Ser Ala Arg Tyr Asp Ala Asn Gin Gly Ser Gly Lys He Asn Val Asn 1475 1480 1485 Gly Tyr Asp Phe Ala Tyr Asn Val Glu Asn Gin Gin Gin Tyr Asn Ala 1490 1495 1500 Gly Leu Lys Leu Lys Tyr His Asn Val Lys Leu Ser Leu He Gly Gly 1505 1510 1515 1520 Leu Thr Lys Ala Lys Gin Ala Glu Lys Gin Lys Thr Ala Glu Leu Lys 1525 1530 1535 Leu Ser Phe Ser Phe 1540 (2) INFORMATION FOR SEQ ID NO:4: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1545 ammo acids (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 : Meu Leu Asn Lys Lys Phe Lys Leu Asn Phe He Ala Leu Thr Val Ala 1 5 10 15 Tyr Ala Leu Thr Pro Tyr Thr Glu Ala Ala Leu Val Arg Asp Asp Val 20 25 30 Asp Tyr Gin He Phe Arg Asp Phe Ala Glu Asn Lys Gly Lys Phe Ser 35 40 45 Val Gly Ala Thr Asn Val Glu Val Arg Asp Lys Asn Asn Arg Pro Leu 50 55 60 Gly Asn Val Leu Pro Asn Gly He Pro Met He Asp Phe Ser Val Val 65 70 75 80 Asp Val Asp Lys Arg He Ala Thr Leu Val Asn Pro Gin Tyr Val Val 85 90 95 Gly Val Lys His Val Ser Asn Gly Val Ser Glu Leu His Phe Gly Asn 100 105 110 Leu Asn Gly Asn Met Asn Asn Gly Asn Ala Lys Ala His Arg Asp Val 115 120 125 Ser Ser Glu Glu Asn Arg Tyr Tyr Thr Val Glu Lys Asn Glu Tyr Pro 130 135 140 Thr Lys Leu Asn Gly Lys Ala Val Thr Thr Glu Asp Gin Ala Gin Lys 145 150 155 160 Arg Arg Glu Asp Tyr Tyr Met Pro Arg Leu Asp Lys Phe Val Thr Glu 165 170 175 Val Ala Pro He Glu Ala Ser Thr Asp Ser Ser Thr Ala Gly Thr Tyr 180 185 190 Asn Asn Lys Asp Lys Tyr Pro Tyr Phe Val Arg Leu Gly Ser Gly Thr 195 200 205 Gln Phe He Tyr Glu Asn Gly Thr Arg Tyr Glu Leu Trp Leu Gly Lys 210 215 220 Glu Gly Gin Lys Ser Asp Ala Gly Gly Tyr Asn Leu Lys Leu Val Gly 225 230 235 240 Asn Ala Tyr Thr Tyr Gly He Ala Gly Thr Pro Tyr Glu Val Asn His 245 250 255 Glu Asn Asp Gly Leu He Gly Phe Gly Asn Ser Asn Asn Glu Tyr He 260 265 270 Asn Pro Lys Glu He Leu Ser Lys Lys Pro Leu Thr Asn Tyr Ala Val 275 280 285 Leu Gly Asp Ser Gly Ser Pro Leu Phe Val Tyr Asp Arg Glu Lys Gly 290 295 300 Lys Trp Leu Phe Leu Gly Ser Tyr Asp Tyr Trp Ala Gly Tyr Asn Lys 305 310 315 320 Lys Ser Trp Gin Glu Trp Asn He Tyr Lys Pro Glu Phe Ala Glu Lys 325 330 335 He Tyr Glu Gin Tyr Ser Ala Gly Ser Leu He Gly Ser Lys Thr Asp 340 345 350 Tyr Ser Trp Ser Ser Asn Gly Lys Thr Ser Thr He Thr Gly Gly Glu 355 360 365 Lys Ser Leu Asn Val Asp Leu Ala Asp Gly Lys Asp Lys Pro Asn His 370 375 380 Gly Lys Ser Val Thr Phe Glu Gly Ser Gly Thr Leu Thr Leu Asn Asn 385 390 395 400 Asn He Asp Gin Gly Ala Gly Gly Leu Phe Phe Glu Gly Asp Tyr Glu 405 410 415 Val Lys Gly Thr Ser Asp Asn Thr Thr Trp Lys Gly Ala Gly Val Ser 420 425 430 Val Ala Glu Gly Lys Thr Val Thr Trp Lys Val His Asn Pro Gin Tyr 435 440 445 Asp Arg Leu Ala Lys He Gly Lys Gly Thr Leu He Val Glu Gly Thr 450 455 460 Gly Asp Asn Lys Gly Ser Leu Lys Val Gly Asp Gly Thr Val He Leu 465 470 475 480 Lys Gin Gin Thr Asn Gly Ser Gly Gin His Ala Phe Ala Ser Val Gly 485 490 495 He Val Ser Gly Arg Ser Thr Leu Val Leu Asn Asp Asp Lys Gin Val 500 505 510 Asp Pro Asn Ser He Tyr Phe Gly Phe Arg Gly Gly Arg Leu Asp Leu 515 520 525 Asn Gly Asn Ser Leu Thr Phe Asp His He Arg Asn He Asp Glu Gly 530 535 540 Ala Arg Leu Val Asn His Ser Thr Ser Lys His Ser Thr Val Thr He 545 550 555 560 Thr Gly Asp Asn Leu He Thr Asp Pro Asn Asn Val Ser He Tyr Tyr 565 570 575 Val Lys Pro Leu Glu Asp Asp Asn Pro Tyr Ala He Arg Gin He Lys 580 585 590 Tyr Gly Tyr Gin Leu Tyr Phe Asn Glu Glu Asn Arg Thr Tyr Tyr Ala 595 600 605 Leu Lys Lys Asp Ala Ser He Arg Ser Glu Phe Pro Gin Asn Arg Gly 610 615 620 Glu Ser Asn Asn Ser Trp Leu Tyr Met Gly Thr Glu Lys Ala Asp Ala 625 630 635 640 Gin Lys Asn Ala Met Asn His He Asn Asn Glu Arg Met Asn Gly Phe 645 650 655 Asn Gly Tyr Phe Gly Glu Glu Glu Gly Lys Asn Asn Gly Asn Leu Asn 660 665 ' 670 Val Thr Phe Lys Gly Lys Ser Glu Gin Asn Arg Phe Leu Leu Thr Gly 675 680 685 Gly Thr Asn Leu Asn Gly Asp Leu Asn Val Gin Gin Gly Thr Leu Phe 690 695 700 Leu Ser Gly Arg Pro Thr Pro His Ala Arg Asp He Ala Gly He Ser 705 710 715 720 Ser Thr Lys Lys Asp Ser His Phe Ser Glu Asn Asn Glu Val Val Val 725 730 735 Glu Asp Asp Trp He Asn Arg Asn Phe Lys Ala Thr Asn He Asn Val 740 745 750 Thr Asn Asn Ala Thr Leu Tyr Ser Gly Arg Asn Val Glu Ser He Thr 755 760 765 Ser Asn He Thr Ala Ser Asn Asn Ala Lys Val His He Gly Tyr Lys 770 775 780 Ala Gly Asp Thr Val Cys Val Arg Ser Asp Tyr Thr Gly Tyr Val Thr 785 790 795 800 Cys Thr Thr Asp Lys Leu Ser Asp Lys Ala Leu Asn Ser Phe Asn Pro 805 810 815 Thr Asn Leu Arg Gly Asn Val Asn Leu Thr Glu Ser Ala Asn Phe Val 820 825 830 Leu Gly Lys Ala Asn Leu Phe Gly Thr He Gin Ser Arg Gly Asn Ser 835 840 845 Gin Val Arg Leu Thr Glu Asn Ser His Trp His Leu Thr Gly Asn Ser 850 855 860 Asp Val His Gin Leu Asp Leu Ala Asn Gly His He His Leu Asn Ser 865 870 875 880 Ala Asp Asn Ser Asn Asn Val Thr Lys Tyr Asn Thr Leu Thr Val Asn 885 890 895 Ser Leu Ser Gly Asn Gly Ser Phe Tyr Tyr Leu Thr Asp Leu Ser Asn 900 905 910 Lys Gin Gly Asp Lys Val Val Val Thr Lys Ser Ala Thr Gly Asn Phe 915 920 925 Thr Leu Gin Val Ala Asp Lys Thr Gly Glu Pro Asn His Asn Glu Leu 930 935 940 Thr Leu Phe Asp Ala Ser Lys Ala Gin Arg Asp His Leu Asn Val Ser 945 950 955 960 Leu Val Gly Asn Thr Val Asp Leu Gly Ala Trp Lys Tyr Lys Leu Arg 965 970 975 Asn Val Asn Gly Arg Tyr Asp Leu Tyr Asn Pro Glu Val Glu Lys Arg 980 985 990 Asn Gin Thr Val Asp Thr Thr Asn He Thr Thr Pro Asn Asn He Gin 995 1000 1005 Ala Asp Val Pro Ser Val Pro Ser Asn Asn Glu Glu He Ala Arg Val 1010 1015 10 C Asp Glu Ala Pro Val Pro Pro Pro Ala Pro Ala Thr Pro Ser Glu Thr 1025 1030 1035 1040 Thr Glu Thr Val Ala Glu Asn Ser Lys Gin Glu Ser Lys Thr Val Glu 1045 1050 1055 Lys Asn Glu Gin Asp Ala Thr Glu Thr Thr Ala Gin Asn Arg Glu Val 1060 1065 1070 Ala Lys Glu Ala Lys Ser Asn Val Lys Ala Asn Thr Gin Thr Asn Glu 1075 1080 1085 Val Ala Gin Ser Gly Ser Glu Thr Lys Glu Thr Gin Thr Thr Glu Thr 1090 1095 1100 Lys Glu Thr Ala Thr Val Glu Lys Glu Glu Lys Ala Lys Val Glu Thr 1105 1110 1115 1120 Glu Lys Thr Gin Glu Val Pro Lys Val Thr Ser Gin Val Ser Pro Lys 1125 1130 1135 Gin Glu Gin Ser Glu Thr Val Gin Pro Gin Ala Glu Pro Ala Arg Glu 1140 1145 1150 Asn Asp Pro Thr Val Asn He Lys Glu Pro Gin Ser Gin Thr Asn Thr 1155 1160 1165 Thr Ala Asp Thr Glu Gin Pro Ala Lys Glu Thr Ser Ser Asn Val Glu 1170 1175 1180 Gin Pro Val Thr Glu Ser Thr Thr Val Asn Thr Gly Asn Ser Val Val 1185 1190 1195 1200 Glu Asn Pro Glu Asn Thr Thr Pro Ala Thr Thr Gin Pro Thr Val Asn 1205 1210 1215 Ser Glu Ser Ser Asn Lys Pro Lys Asn Arg His Arg Arg Ser Val Arg 1220 1225 1230 Ser Val Pro His Asn Val Glu Pro Ala Thr Thr Ser Ser Asn Asp Arg 1235 1240 1245 Ser Thr Val Ala Leu Cys Asp Leu Thr Ser Thr Asn Thr Asn Ala Val 1250 1255 1260 Leu Ser Asp Ala Arg Ala Lys Ala Gin Phe Val Ala Leu Asn Val Gly 1265 1270 1275 1280 Lys Ala Val Ser Gin His He Ser Gin Leu Glu Met Asn Asn Glu Gly 1285 1290 1295 Gin Tyr Asn Val Trp Val Ser Asn Thr Ser Met Asn Lys Asn Tyr Ser 1300 1305 1310 Ser Ser Gin Tyr Arg Arg Phe Ser Ser Lys Ser Thr Gin Thr Gin Leu 1315 1320 1325 Gly Trp Asp Gin Thr He Ser Asn Asn Val Gin Leu Gly Gly Val Phe 1330 1335 1340 Thr Tyr Val Arg Asn Ser Asn Asn Phe Asp Lys Ala Thr Ser Lys Asn 1345 1350 1355 1360 Thr Leu Ala Gin Val Asn Phe Tyr Ser Lys Tyr Tyr Ala Asp Asn His 1365 1370 * ' 1375 Trp Tyr Leu Gly He Asp Leu Gly Tyr Gly Lys Phe Gin Ser Lys Leu 1380 1385 1390 Gin Thr Asn His Asn Ala Lys Phe Ala Arg His Thr Ala Gin Phe Gly 1395 1400 1405 Leu Thr Ala Gly Lys Ala Phe Asn Leu Gly Asn Phe Gly He Thr Pro 1410 1415 1420 He Val Gly Val Arg Tyr Ser Tyr Leu Ser Asn Ala Asp Phe Ala Leu 1425 1430 1435 1440 Asp Gin Ala Arg He Lys Val Asn Pro He Ser Val Lys Thr Ala Phe 1445 1450 1455 Ala Gin Val Asp Leu Ser Tyr Thr Tyr His Leu Gly Glu Phe Ser Val 1460 1465 1470 Thr Pro He Leu Ser Ala Arg Tyr Asp Ala Asn Gin Gly Ser Gly Lys 1475 1480 1485 He Asn Val Asn Gly Tyr Asp Phe Ala Tyr Asn Val Glu Asn Gin Gin 1490 1495 1500 Gin Tyr Asn Ala Gly Leu Lys Leu Lys Tyr His Asn Val Lys Leu Ser 1505 1510 1515 1520 Leu He Gly Gly Leu Thr Lys Ala Lys Gin Ala Glu Lys Gin Lys Thr 1525 1530 1535 Ala Glu Leu Lys Leu Ser Phe Ser Phe 1540 1545 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1702 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Met Leu Asn Lys Lys Phe Lys Leu Asn Phe He Ala Leu Thr Val Ala 1 5 10 15 Tyr Ala Leu Thr Pro Tyr Thr Glu Ala Ala Leu Val Arg Asp Asp Val 20 25 30 Asp Tyr Gin He Phe Arg Asp Phe Ala Glu Asn Lys Gly Arg Phe Ser 35 40 45 Val Gly Ala Thr Asn Val Glu Val Arg Asp Lys Asn Asn His Ser Leu 50 55 60 Gly Asn Val Leu Pro Asn Gly He Pro Met He Asp Phe Ser Val Val 65 70 75 80 Asp Val Asp Lys Arg He Ala Thr Leu He Asn Pro Gin Tyr Val Val 85 90 95 Gly Val Lys His Val Ser Asn Gly Val Ser Glu Leu His Phe Gly Asn 100 105 110 Leu Asn Gly Asn Met Asn Asn Gly Asn Asp Lys Ser His Arg Asp Val 115 120 125 Ser Ser Glu Glu Asn Arg Tyr Phe Ser Val Glu Lys Asn Glu Tyr Pro 130 135 140 Thr Lys Leu Asn Gly Lys Ala Val Thr Thr Glu Asp Gin Thr Gin Lys 145 150 155 160 Arg Arg Glu Asp Tyr Tyr Met Pro Arg Leu Asp Lys Phe Val Thr Glu 165 170 175 Val Ala Pro He Glu Ala Ser Thr Ala Ser Ser Asp Ala Gly Thr Tyr 180 185 190 Asn Asp Gin Asn Lys Tyr Pro Ala Phe Val Arg Leu Gly Ser Gly Thr 195 200 205 Gin Phe He Tyr Lys Lys Gly Asp Asn Tyr Ser Leu He Leu Asn Asn 210 215 220 His Glu Val Gly Gly Asn Asn Leu Lys Leu Val Gly Asp Ala Tyr Thr 225 230 235 240 Tyr Gly He Ala Gly Thr Pro Tyr Lys Val Asn His Glu Asn Asn Gly 245 250 255 Leu He Gly Phe Gly Asn Ser Lys Glu Glu His Ser Asp Pro Lys Gly 260 265 270 He Leu Ser Gin Asp Pro Leu Thr Asn Tyr Ala Val Leu Gly Asp Ser 275 280 285 Gly Ser Pro Leu Phe Val Tyr Asp Arg Glu Lys Gly Lys Trp Leu Phe 290 295 300 Leu Gly Ser Tyr Asp Phe Trp Ala Gly Tyr Asn Lys Lys Ser Trp Gin 305 310 315 320 Glu Trp Asn He Tyr Lys Pro Glu Phe Ala Lys Thr Val Leu Asp Lys 325 330 335 Asp Thr Ala Gly Ser Leu He Gly Ser Asn Thr Gin Tyr Asn Trp Asn 340 345 350 Pro Thr Gly Lys Thr Ser Val He Ser Asn Gly Ser Glu Ser Leu Asn 355 360 365 Val Asp Leu Phe Asp Ser Ser Gin Asp Thr Asp Ser Lys Lys Asn Asn 370 375 380 His Gly Lys Ser Val Thr Leu Arg Gly Ser Gly Thr Leu Thr Leu Asn 385 390 395 400 Asn Asn He Asp Gin Gly Ala Gly Gly Leu Phe Phe Glu Gly Asp Tyr 405 410 415 Glu Val Lys Gly Thr Ser Asp Ser Thr Thr Trp Lys Gly Ala Gly Val 420 425 430 Ser Val Ala Asp Gly Lys Thr Val Thr Trp Lys Val His Asn Pro Lys 435 440 445 Ser Asp Arg Leu Ala Lys He Gly Lys Gly Thr Leu He Val Glu Gly 450 455 460 Lys Gly Glu Asn Lys Gly Ser Leu Lys Val Gly Asp Gly Thr Val He 465 470 475 465 Leu Lys Gin Gin Ala Asp Ala Asn Asn Lys Val Lys Ala Phe Ser Gin 485 490 495 Val Gly He Val Ser Gly Arg Ser Thr Val Val Leu Asn Asp Asp Lys 500 505 510 Gin Val Asp Pro Asn Ser He Tyr Phe Gly Phe Arg Gly Gly Arg Leu 515 520 525 Asp Ala Asn Gly Asn Asn Leu Thr Phe Glu His He Arg Asn He Asp 530 535 540 Asp Gly Ala Arg Leu Val Asn His Asn Thr Ser Lys Thr Ser Thr Val 545 550 555 560 Thr He Thr Gly Glu Ser Leu He Thr Asp Pro Asn Thr He Thr Pro 565 570 575 Tyr Asn He Asp Ala Pro Asp Glu Asp Asn Pro Tyr Ala Phe Arg Arg 580 585 590 He Lys Asp Gly Gly Gin Leu Tyr Leu Asn Leu Glu Asn Tyr Thr Tyr 595 600 605 Tyr Ala Leu Arg Lys Gly Ala Ser Thr Arg Ser Glu Leu Pro Lys Asn 610 615 620 Ser Gly Glu Ser Asn Glu Asn Trp Leu Tyr Met Gly Lys Thr Ser Asp 625 630 635 640 Ala Ala Lys Arg Asn Val Met Asn His He Asn Asn Glu Arg Met Asn 645 650 655 Gly Phe Asn Gly Tyr Phe Gly Glu Glu Glu Gly Lys Asn Asn Gly Asn 660 665 670 Leu Asn Val Thr Phe Lys Gly Lys Ser Glu Gin Asn Arg Phe Leu Leu 675 680 685 Thr Gly Gly Thr Asn Leu Asn Gly Asp Leu Lys Val Glu Lys Gly Thr 690 695 700 Leu Phe Leu Ser Gly Arg Pro Thr Pro His Ala Arg Asp He Ala Gly 705 710 715 720 Ile Ser Ser Thr Lys Lys Asp Gin His Phe Ala Glu Asn Asn Glu Val 725 730 735 Val Val Glu Asp Asp Trp He Asn Arg Asn Phe Lys Ala Thr Asn He 740 745 750 Asn Val Thr Asn Asn Ala Thr Leu Tyr Ser Gly Arg Asn Val Ala Asn 755 760 765 He Thr Ser Asn He Thr Ala Ser Asp Asn Ala Lys Val His He Gly 770 775 780 Tyr Lys Ala Gly Asp Thr Val Cys Val Arg Ser Asp Tyr Thr Gly Tyr 785 790 795 800 Val Thr Cys Thr Thr Asp Lys Leu Ser Asp Lys Ala Leu Asn Ser Phe 805 810 815 Asn Ala Thr Asn Val Ser Gly Asn Val Asn Leu Ser Gly Asn Ala Asn 820 625 830 Phe Val Leu Gly Lys Ala Asn Leu Phe Gly Thr He Ser Gly Thr Gly 835 840 845 Asn Ser Gin Val Arg Leu Thr Glu Asn Ser His Trp His Leu Thr Gly 850 855 860 Asp Ser Asn Val Asn Gin Leu Asn Leu Asp Lys Gly His He His Leu 865 870 875 880 Asn Ala Gin Asn Asp Ala Asn Lys Val Thr Thr Tyr Asn Thr Leu Thr 885 890 895 Val Asn Ser Leu Ser Gly Asn Gly Ser Phe Tyr Tyr Leu Thr Asp Leu 900 905 910 Ser Asn Lys Gin Gly Asp Lys Val Val Val Thr Lys Ser Ala Thr Gly 915 920 925 Asn Phe Thr Leu Gin Val Ala Asp Lys Thr Gly Glu Pro Thr Lys Asn 930 935 940 Glu Leu Thr Leu Phe Asp Ala Ser Asn Ala Thr Arg Asn Asn Leu Asn 945 950 955 960 Val Ser Leu Val Gly Asn Thr Val Asp Leu Gly Ala Trp Lys Tyr Lys 965 970 975 Leu Arg Asn Val Asn Gly Arg Tyr Asp Leu Tyr Asn Pro Glu Val Glu 980 985 990 Lys Arg Asn Gin Thr Val Asp Thr Thr Asn He Thr Thr Pro Asn Asn 995 1000 1005 He Gin Ala Asp Val Pro Ser Val Pro Ser Asn Asn Glu Glu He Ala 1010 1015 1020 Arg Val Glu Thr Pro Val Pro Pro Pro Ala Pro Ala Thr Pro Ser Glu 1025 1030 1035 1040 Thr Thr Glu Thr Val Ala Glu Asn Ser Lys Gin Glu Ser Lys Thr Val 1045 1050 1055 Glu Lys Asn Glu Gin Asp Ala Thr Glu Thr Thr Ala Gin Asn Gly Glu 1060 1065 1070 Val Ala Glu Glu Ala Lys Pro Ser Val Lys Ala Asn Thr Gin Thr Asn 1075 1080 1085 Glu Val Ala Gin Ser Gly Ser Glu Thr Glu Glu Thr Gin Thr Thr Glu 1090 1095 1100 He Lys Glu Thr Ala Lys Val Glu Lys Glu Glu Lys Ala Lys Val Glu 1105 1110 1115 1120 Lys Glu Glu Lys Ala Lys Val Glu Lys Asp Glu He Gin Glu Ala Pro 1125 1130 1135 Gin Met Ala Ser Glu Thr Ser Pro Lys Gin Ala Lys Pro Ala Pro Lys 1140 1145 1150 Glu Val Ser Thr Asp Thr Lys Val Glu Glu Thr Gin Val Gin Ala Gin 1155 1160 1165 Pro Gin Thr Gin Ser Thr Thr Val Ala Ala Ala Glu Ala Thr Ser Pro 1170 1175 1180 Asn Ser Lys Pro Ala Glu Glu Thr Gin Pro Ser Glu Lys Thr Asn Ala 1185 1190 1195 1200 Glu Pro Val Thr Pro Val Val Ser Lys Asn Gin Thr Glu Asn Thr Thr 1205 1210 1215 Asp Gin Pro Thr Glu Arg Glu Lys Thr Ala Lys Val Glu Thr Glu Lys 1220 1225 1230 Thr Gin Glu Pro Pro Gin Val Ala Ser Gin Ala Ser Pro Lys Gin Glu 1235 1240 1245 Gin Ser Glu Thr Val Gin Pro Gin Ala Val Leu Glu Ser Glu Asn Val 1250 1255 1260 Pro Thr Val Asn Asn Ala Glu Glu Val Gin Ala Gin Leu Gin Thr Gin 1265 1270 1275 1280 Thr Ser Ala Thr Val Ser Thr Lys Gin Pro Ala Pro Glu Asn Ser He 1285 1290 1295 Asn Thr Gly Ser Ala Thr Ala He Thr Glu Thr Ala Glu Lys Ser Asp 1300 1305 1310 Lys Pro Gin Thr Glu Thr Ala Ala Ser Thr Glu Asp Ala Ser Gin His 1315 1320 1325 Lys Ala Asn Thr Val Ala Asp Asn Ser Val Ala Asn Asn Ser Glu Ser 1330 1335 1340 Ser Glu Pro Lys Ser Arg Arg Arg Arg Ser He Ser Gin Pro Gin Glu 1345 1350 1355 1360 Thr Ser Ala Glu Glu Thr Thr Ala Ala Ser Thr Asp Glu Thr Thr He 1365 1370 1375 Ala Asp Asn Ser Lys Arg Ser Lys Pro Asn Arg Arg Ser Arg Arg Ser 1380 1385 1390 Val Arg Ser Glu Pro Thr Val Thr Asn Gly Ser Asp Arg Ser Thr Val 1395 1400 1405 Ala Leu Arg Asp Leu Thr Ser Thr Asn Thr Asn Ala Val He Ser Asp 1410 1415 1420 Ala Met Ala Lys Ala Gin Phe Val Ala Leu Asn Val Gly Lys Ala Val 1425 1430 1435 1440 Ser Gin His He Ser Gin Leu Glu Met Asn Asn Glu Gly Gin Tyr Asn 1445 1450 1455 Val Trp Val Ser Asn Thr Ser Met Asn Glu Asn Tyr Ser Ser Ser Gin 1460 1465 1470 Tyr Arg Arg Phe Ser Ser Lys Ser Thr Gin Thr Gin Leu Gly Trp Asp 1475 1480 1485 Gin Thr He Ser Asn Asn Val Gin Leu Gly Gly Val Phe Thr Tyr Val 1490 1495 1500 Arg Asn Ser Asn Asn Phe Asp Lys Ala Ser Ser Lys Asn Thr Leu Ala 1505 1510 1515 1520 Gin Val Asn Phe Tyr Ser Lys Tyr Tyr Ala Asp Asn His Trp Tyr Leu 1525 1530 1535 Gly He Asp Leu Gly Tyr Gly Lys Phe Gin Ser Asn Leu Lys Thr Asn 1540 1545 1550 His Asn Ala Lys Phe Ala Arg His Thr Ala Gin Phe Gly Leu Thr Ala 1555 1560 1565 Gly Lys Ala Phe Asn Leu Gly Asn Phe Gly He Thr Pro He Val Gly 1570 1575 1580 Val Arg Tyr Ser Tyr Leu Ser Asn Ala Asn Phe Ala Leu Ala Lys Asp 1585 1590 1595 1600 Arg He Lys Val Asn Pro He Ser Val Lys Thr Ala Phe Ala Gin Val 1605 1610 1615 Asp Leu Ser Tyr Thr Tyr His Leu Gly Glu Phe Ser Val Thr Pro He 1620 1625 1630 Leu Ser Ala Arg Tyr Asp Thr Asn Gin Gly Ser Gly Lys He Asn Val 1635 1640 1645 Asn Gin Tyr Asp Phe Ala Tyr Asn Val Glu Asn Gin Gin Gin Tyr Asn 1650 1655 1660 Ala Gly Leu Lys Leu Lys Tyr His Asn Val Lys Leu Ser Leu He Gly 1665 1670 1675 1680 Gly Leu Thr Lys Ala Lys Gin Ala Glu Lys Gin Lys Thr Ala Glu Leu 1685 1690 1695 Lys Leu Ser Phe Ser Phe 1700 (2) INFORMATION FOR SEQ ID NO:6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1848 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Leu Asn Lys Lys Phe Lys Leu Asn Phe He Ala Leu Thr Val Ala 1 5 10 15 Tyr Ala Leu Thr Pro Tyr Thr Glu Ala Ala Leu Val Arg Asp Asp Val 20 25 30 Asp Tyr Gin He Phe Arg Asp Phe Ala Glu Asn Lys Gly Lys Phe Ser 35 40 45 Val Gly Ala Thr Asn Val Glu Val Arg Asp Lys Lys Asn Gin Ser Leu 50 55 60 Gly Ser Ala Leu Pro Asn Gly He Pro Met He Asp Phe Ser Val Val 65 70 75 80 Asp Val Asp Lys Arg He Ala Thr Leu Val Asn Pro Gin Tyr Val Val 85 90 95 Gly Val Lys His Val Ser Asn Gly Val Ser Glu Leu His Phe Gly Asn 100 105 110 Leu Asn Gly Asn Met Asn Asn Gly Asn Ala Lys Ser His Arg Asp Val 115 120 125 Ser Ser Glu Glu Asn Arg Tyr Tyr Thr Val Glu Lys Asn Asn Phe Pro 130 135 140 Thr Glu Asn Val Thr Ser Phe Thr Lys Glu Glu Gin Asp Ala Gin Lys 145 150 155 160 Arg Arg Glu Asp Tyr Tyr Met Pro Arg Leu Asp Lys Phe Val Thr Glu 165 170 175 Val Ala Pro He Glu Ala Ser Thr Ala Asn Asn Asn Lys Gly Glu Tyr 180 185 190 Asn Asn Ser Asp Lys Tyr Pro Ala Phe Val Arg Leu Gly Ser Gly Thr 195 200 205 Gin Phe He Tyr Lys Lys Gly Ser Arg Tyr Gin Leu He Leu Thr Glu 210 215 220 Lys Asp Lys Gin Gly Asn Leu Leu Arg Asn Trp Asp Val Gly Gly Asp 225 230 235 240 Asn Leu Glu Leu Val Gly Asn Ala Tyr Thr Tyr Gly He Ala Gly Thr 245 250 255 Pro Tyr Lys Val Asn His Glu Asn Asn Gly Leu He Gly Phe Gly Asn 260 265 270 Ser Lys Glu Glu His Ser Asp Pro Lys Gly He Leu Ser Gin Asp Pro 275 280 285 Leu Thr Asn Tyr Ala Val Leu Gly Asp Ser Gly Ser Pro Leu Phe Val 290 295 300 Tyr Asp Arg Glu Lys Gly Lys Trp Leu Phe Leu Gly Ser Tyr Asp Phe 305 310 315 320 Trp Ala Gly Tyr Asn Lys Lys Ser Trp Gin Glu Trp Asn He Tyr Lys 325 330 335 His Glu Phe Ala Glu Lys He Tyr Gin Gin Tyr Ser Ala Gly Ser Leu 340 345 350 He Gly Ser Asn Thr Gin Tyr Thr Trp Gin Ala Thr Gly Ser Thr Ser 355 360 365 Thr He Thr Gly Gly Gly Glu Pro Leu Ser Val Asp Leu Thr Asp Gly 370 375 380 Lys Asp Lys Pro Asn His Gly Lys Ser He Thr Leu Lys Gly Ser Gly 385 390 395 400 Thr Leu Thr Leu Asn Asn His He Asp Gin Gly Ala Gly Gly Leu Phe 405 410 415 Phe Glu Gly Asp Tyr Glu Val Lys Gly Thr Ser Asp Ser Thr Thr Trp 420 425 430 Lys Gly Ala Gly Val Ser Val Ala Asp Gly Lys Thr Val Thr Trp Lys 435 440 445 Val His Asn Pro Lys Tyr Asp Arg Leu Ala Lys He Gly Lys Gly Thr 450 455 460 Leu Val Val Glu Gly Lys Gly Lys Asn Glu Gly Leu Leu Lys Val Gly 465 470 475 480 Asp Gly Thr Val He Leu Lys Gin Lys Ala Asp Ala Asn Asn Lys Val 485 490 495 Gin Ala Phe Ser Gin Val Gly He Val Ser Gly Arg Ser Thr Leu Val 500 505 510 Leu Asn Asp Asp Lys Gin Val Asp Pro Asn Ser He Tyr Phe Gly Phe 515 520 525 Arg Gly Gly Arg Leu Asp Leu Asn Gly Asn Ser Leu Thr Phe Asp His 530 535 540 He Arg Asn He Asp Asp Gly Ala Arg Val Val Asn His Asn Met Thr 545 550 555 560 Asn Thr Ser Asn He Thr He Thr Gly Glu Ser Leu He Thr Asn Pro 565 570 575 Asn Thr He Thr Ser Tyr Asn He Glu Ala Gin Asp Asp Asp His Pro 580 585 590 Leu Arg He Arg Ser He Pro Tyr Arg Gin Leu Tyr Phe Asn Gin Asp 595 600 605 Asn Arg Ser Tyr Tyr Thr Leu Lys Lys Gly Ala Ser Thr Arg Ser Glu 610 615 620 Leu Pro Gin Asn Ser Gly Glu Ser Asn Glu Asn Trp Leu Tyr Met Gly 625 ' 630 635 640 Arg Thr Ser Asp Ala Ala Lys Arg Asn Val Met Asn His He Asn Asn 645 650 655 Glu Arg Met Asn Gly Phe Asn Gly Tyr Phe Gly Glu Glu Glu Thr Lys 660 665 670 Ala Thr Gin Asn Gly Lys Leu Asn Val Thr Phe Asn Gly Lys Ser Asp 675 680 685 Gin Asn Arg Phe Leu Leu Thr Gly Gly Thr Asn Leu Asn Gly Asp Leu 690 695 700 Asn Val Glu Lys Gly Thr Leu Phe Leu Ser Gly Arg Pro Thr Pro His 705 710 715 720 Ala Arg Asp He Ala Gly He Ser Ser Thr Lys Lys Asp Pro His Phe 725 730 735 Thr Glu Asn Asn Glu Val Val Val Glu Asp Asp Trp He Asn Arg Asn 740 745 750 Phe Lys Ala Thr Thr Met Asn Val Thr Gly Asn Ala Ser Leu Tyr Ser 755 760 765 Gly Arg Asn Val Ala Asn He Thr Ser Asn He Thr Ala Ser Asn Asn 770 775 780 Ala Gin Val His He Gly Tyr Lys Thr Gly Asp Thr Val Cys Val Arg 785 790 795 800 Ser Asp Tyr Thr Gly Tyr Val Thr Cys His Asn Ser Asn Leu Ser Glu 805 810 815 Lys Ala Leu Asn Ser Phe Asn Pro Thr Asn Leu Arg Gly Asn Val Asn 820 825 83C Leu Thr Glu Asn Ala Ser Phe Thr Leu Gly Lys Ala Asn Leu Phe Gly 835 840 ' 845 Thr He Gin Ser He Gly Thr Ser Gin Val Asn Leu Lys Glu Asn Ser 850 855 860 His Trp His Leu Thr Gly Asn Ser Asn Val Asn Gin Leu Asn Leu Thr 865 870 875 880 Asn Gly His He His Leu Asn Ala Gin Asn Asp Ala Asn Lys Val Thr 885 890 895 Thr Tyr Asn Thr Leu Thr Val Asn Ser Leu Ser Gly Asn Gly Ser Phe 900 905 910 Tyr Tyr Trp Val Asp Phe Thr Asn Asn Lys Ser Asn Lys Val Val Val 915 920 925 Asn Lys Ser Ala Thr Gly Asn Phe Thr Leu Gin Val Ala Asp Lys Thr 930 935 940 Gly Glu Pro Asn His Asn Glu Leu Thr Leu Phe Asp Ala Ser Asn Ala 945 950 955 960 Thr Arg Asn Asn Leu Glu Val Thr Leu Ala Asn Gly Ser Val Asp Arg 965 970 975 Gly Ala Trp Lys Tyr Lys Leu Arg Asn Val Asn Gly Arg Tyr Asp Leu 980 985 990 Tyr Asn Pro Glu Val Glu Lys Arg Asn Gin Thr Val Asp Thr Thr Asn 995 1000 1005 He Thr Thr Pro Asn Asp He Gin Ala Asp Ala Pro Ser Ala Gin Ser 1010 1015 1020 Asn Asn Glu Glu He Ala Arg Val Glu Thr Pro Val Pro Pro Pro Ala 1025 1030 1035 1040 Pro Ala Thr Glu Ser Ala He Ala Ser Glu Gin Pro Glu Thr Arg Pro 1045 1050 1055 Ala Glu Thr Ala Gin Pro Ala Met Glu Glu Thr Asn Thr Ala Asn Ser 1060 1065 1070 Thr Glu Thr Ala Pro Lys Ser Asp Thr Ala Thr Gin Thr Glu Asn Pro 1075 1080 1085 Asn Ser Glu Ser Val Pro Ser Glu Thr Thr Glu Lys Val Ala Glu Asn 1090 1095 1100 Pro Pro Gin Glu Asn Glu Thr Val Ala Lys Asn Glu Gin Glu Ala Thr 1105 1110 1115 1120 Glu Pro Thr Pro Gin Asn Gly Glu Val Ala Lys Glu Asp Gin Pro Thr 1125 1130 1135 Val Glu Ala Asn Thr Gin Thr Asn Glu Ala Thr Gin Ser Glu Gly Lys 1140 1145 1150 Thr Glu Glu Thr Gin Thr Ala Glu Thr Lys Ser Glu Pro Thr Glu Ser 1155 1160 1165 Val Thr Val Ser Glu Asn Gin Pro Glu Lys Thr Val Ser Gin Ser Thr 1170 1175 llcC Glu Asp Lys Val Val Val Glu Lys Glu Glu Lys Ala Lys Val Glu Thr 1185 1190 1195 1200 Glu Glu Thr Gin Lys Ala Pro Gin Val Thr Ser Lys Glu Pro Pro Lys 1205 1210 1215 Gin Ala Glu Pro Ala Pro Glu Glu Val Pro Thr Asp Thr Asn Ala Glu 1220 1225 1230 Glu Ala Gin Ala Leu Gin Gin Thr Gin Pro Thr Thr Val Ala Ala Ala 1235 1240 1245 Glu Thr Thr Ser Pro Asn Ser Lys Pro Ala Glu Glu Thr Gin Gin Pro 1250 1255 1260 Ser Glu Lys Thr Asn Ala Glu Pro Val Thr Pro Val Val Ser Glu Asn 1265 1270 1275 1280 Thr Ala Thr Gin Pro Thr Glu Thr Glu Glu Thr Ala Lys Val Glu Lys 1285 1290 1295 Glu Lys Thr Gin Glu Val Pro Gin Val Ala Ser Gin Glu Ser Pro Lys 1300 1305 1310 Gin Glu Gin Pro Ala Ala Lys Pro Gin Ala Gin Thr Lys Pro Gin Ala 1315 1320 1325 Glu Pro Ala Arg Glu Asn Val Leu Thr Thr Lys Asn Val Gly Glu Pro 1330 1335 1340 Gin Pro Gin Ala Gin Pro Gin Thr Gin Ser Thr Ala Val Pro Thr Thr 1345 1350 1355 1360 Gly Glu Thr Ala Ala Asn Ser Lys Pro Ala Ala Lys Pro Gin Ala Gin 1365 1370 1375 Ala Lys Pro Gin Thr Glu Pro Ala Arg Glu Asn Val Ser Thr Val Asn 1380 1385 1390 Thr Lys Glu Pro Gin Ser Gin Thr Ser Ala Thr Val Ser Thr Glu Gin 1395 1400 1405 Pro Ala Lys Glu Thr Ser Ser Asn Val Glu Gin Pro Ala Pro Glu Asn 1410 1415 1420 Ser He Asn Thr Gly Ser Ala Thr Thr Met Thr Glu Thr Ala Glu Lys 1425 1430 1435 1440 Ser Asp Lys Pro Gin Met Glu Thr Val Thr Glu Asn Asp Arg Gin Pro 1445 1450 1455 Glu Ala Asn Thr Val Ala Asp Asn Ser Val Ala Asn Asn Ser Glu Ser 1460 1465 1470 Ser Glu Ser Lys Ser Arg Arg Arg Arg Ser Val Ser Gin Pro Lys Glu 1475 1480 1485 Thr Ser Ala Glu Glu Thr Thr Val Ala Ser Thr Gin Glu Thr Thr Val 1490 1495 1500 Asp Asn Ser Val Ser Thr Pro Lys Pro Arg Ser Arg Arg Thr Arg Arg 1505 1510 1515 1520 Ser Val Gin Thr Asn Ser Tyr Glu Pro Val Glu Leu Pro Thr Glu Asn 1525 153& 1535 Ala Glu Asn Ala Glu Asn Val Gin Ser Gly Asn Asn Val Ala Asn Ser 1540 1545 1550 Gin Pro Ala Leu Arg Asn Leu Thr Ser Lys Asn Thr Asn Ala Val He 1555 1560 1565 Ser Asn Ala Met Ala Lys Ala Gin Phe Val Ala Leu Asn Val Gly Lys 1570 1575 1580 Ala Val Ser Gin His He Ser Gin Leu Glu Met Asn Asn Glu Gly Gin 1585 1590 1595 1600 Tyr Asn Val Trp He Ser Asn Thr Ser Met Asn Lys Asn Tyr Ser Ser 1605 1610 1615 Glu Gin Tyr Arg Arg Phe Ser Ser Lys Ser Thr Gin Thr Gin Leu Gly 1620 1625 1630 Trp Asp Gin Thr He Ser Asn Asn Val Gin Leu Gly Gly Val Phe Thr 1635 1640 1645 Tyr Val Arg Asn Ser Asn Asn Phe Asp Lys Ala Ser Ser Lys Asn Thr 1650 1655 1660 Leu Ala Gin Val Asn Phe Tyr Ser Lys Tyr Tyr Ala Asp Asn His Trp 1665 1670 1675 1680 Tyr Leu Gly He Asp Leu Gly Tyr Gly Lys Phe Gin Ser Asn Leu Gin 1685 1690 1695 Thr Asn Asn Asn Ala Lys Phe Ala Arg His Thr Ala Gin He Gly Leu 1700 1705 1710 Thr Ala Gly Lys Ala Phe Asn Leu Gly Asn Phe Ala Val Lys Pro Thr 1715 1720 1725 Val Gly Val Arg Tyr Ser Tyr Leu Ser Asn Ala Asp Phe Ala Leu Ala 1730 1735 1740 Gin Asp Arg He Lys Val Asn Pro He Ser Val Lys Thr Ala Phe Ala 1745 1750 1755 1760 Gin Val Asp Leu Ser Tyr Thr Tyr His Leu Gly Glu Phe Ser He Thr 1765 1770 1775 Pro He Leu Ser Ala Arg Tyr Asp Ala Asn Gin Gly Asn Gly Lys He 1780 1785 1790 Asn Val Ser Val Tyr Asp Phe Ala Tyr Asn Val Glu Asn Gin Gin Gin 1795 1800 1805 Tyr Asn Ala Gly Leu Lys Leu Lys Tyr His Asn Val Lys Leu Ser Leu 1810 1815 1820 He Gly Gly Leu Thr Lys Ala Lys Gin Ala Glu Lys Gin Lys Thr Ala 1825 1830 1835 1840 Glu Val Lys Leu Ser Phe Ser Phe 1845 INFORMATION FOR SEQ ID NO: 7 : (i) SEQUENCE CHARACTERISTICS (A) LENGTH- 8 amino acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 Gly Asp Ser Gly Ser Pro Met Phe 1 5 (2) INFORMATION FOR SEQ ID NO:8 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 : Gly Asp Ser Gly Ser Pro Leu Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 9 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9 : His Thr Tyr Phe Gly He Asp 1 5

Claims: CLAIMS 1. A recombinant Haemophilus adhesion and penetration protein. 2. A recombinant Haemophilus adhesion and penetration protein according to claim 1 which has a sequence homologous to that shown in Figure 6. 3. A recombinant Haemophi l us adhesion and penetration protein according to claim 1 which has the sequence shown in Figure 6. 4. A recombinant nucleic acid encoding an Haemophil us adhesion and penetration protein. 5. The nucleic acid of claim 3 comprising DNA having a sequence homologous to that shown in Figure 6. 6. An expression vector comprising transcriptional and translational regulatory nucleic acid operably linked to nucleic acid encoding an Haemophil us adhesion and penetration protein. 7. A host cell transformed with an expression vector comprising a nucleic acid encoding an Haemophilus adhesion and penetration protein. 8. A method of producing an Haemophilus adhesion and penetration protein comprising: a) culturing a host cell transformed with an expressing vector comprising a nucleic acid encoding an Haemophilus adhesion and penetration protein; and b) expressing said nucleic acid to produce an Haemophilus adhesion and penetration protein. 9. A vaccine comprising a pharmaceutically acceptable carrier and an Haemophil us adhesion and penetration protein for prophylactic or therapeutic use in generating an immune response. 10. A vaccine according to claim 8 wherein said Haemophil us adhesion and penetration protein has a sequence homologous to that shown in Figure 6. 11. A monoclonal antibody capable of binding to an Haemophilus adhesion and penetration protein. 12. A method of treating or preventing Haemophil us influenzae infection comprising administering the vaccine of claim 9 or 10.

Inventors: FALKOW STANLEY, ST GEME JOSEPH W III, FALKOW, STANLEY, ST. GEME, JOSEPH, W., III
Applicants: UNIV LELAND STANFORD JUNIOR, UNIV WASHINGTON, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO, WASHINGTON UNIVERSITY
Application year: 1995
Main classification: A61K39
IPC codes: A61K38, A61K39, A61P31, C07K7, C07K14, C07K16, C12N1, C12N9, C12N15, C12P21, C12R1, G01N33